var title_f39_20_40256="RLL BAC CT";
var content_f39_20_40256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchioloalveolar carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with the consolidative form of bronchioloalveolar carcinoma in the right lung. CT scan shows a mass in the posterobasal and laterobasal segments of the right lower lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40256=[""].join("\n");
var outline_f39_20_40256=null;
var title_f39_20_40257="Calcified pleural plaque CT";
var content_f39_20_40257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcified pleural plaque",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right-sided calcified pleural plaque with adjacent calcification in the lung parenchyma, likely representing a granuloma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40257=[""].join("\n");
var outline_f39_20_40257=null;
var title_f39_20_40258="Collagen hemostat: Drug information";
var content_f39_20_40258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Collagen hemostat: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avitene&reg;;",
"     </li>",
"     <li>",
"      Avitene&reg; Flour;",
"     </li>",
"     <li>",
"      Avitene&reg; Ultrafoam&trade;;",
"     </li>",
"     <li>",
"      EndoAvitene&reg;;",
"     </li>",
"     <li>",
"      Helistat&reg;;",
"     </li>",
"     <li>",
"      Helitene&reg;;",
"     </li>",
"     <li>",
"      Instat&trade; MCH;",
"     </li>",
"     <li>",
"      SyringeAvitene&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F196390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Hemostatic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F196384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemostasis: Topical: Apply dry directly to source of bleeding; remove excess material after ~10-15 minutes",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F196385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, topical [microfibrillar product, bovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avitene&reg; Flour:  (0.5 g, 1 g, 5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Helitene&reg;:  (0.5 g, 1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Instat&trade; MCH:  (0.5 g, 1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SyringeAvitene&trade;:  (1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sheet, topical [microfibrillar product, bovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avitene&reg;:  (1s) [35 mm x 35 mm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avitene&reg;:  (6s, 12s [DSC]) [70 mm x 35 mm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avitene&reg;:  (6s, 12s [DSC]) [70 mm x 70 mm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EndoAvitene&reg;:  (6s) [10 mm diameter; 50 mm x 15 mm x 1 mm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EndoAvitene&reg;:  (6s) [5 mm diameter; 50 mm x 5 mm x 1 mm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sponge, topical [bovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Helistat&reg;:  (18s) [0.5 inch x 1 inch x 7 mm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Helistat&reg;:  (10s) [3 inch x 4 inch x 5 mm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sponge, topical [microfibrillar product, bovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avitene&reg; Ultrafoam&trade;:  (6s) [2 cm x 6.25 cm x 7 cm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avitene&reg; Ultrafoam&trade;:  (6s) [8 cm x 12.5 cm x 1 cm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avitene&reg; Ultrafoam&trade;:  (6s) [8 cm x 12.5 cm x 3 cm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avitene&reg; Ultrafoam&trade;:  (6s) [8 cm x 6.25 cm x 7 cm]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F196374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to hemostasis when control of bleeding by ligature is ineffective or impractical",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F196395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Avitene&reg; may be confused with Ativan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Over 100 reports of paralysis or other neural deficits have been received by the FDA, attributable to collagen hemostat-associated neuronal impingement; see Warnings/Precautions",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F196388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Adhesion formation, allergic reaction, edema, foreign body reaction, hematoma, inflammation, potentiation of infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Numbness, pain, paralysis, subgaleal seroma; alveolalgia and transient laryngospasm with dental use",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F196377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; products of bovine origin; closure of skin incisions, contaminated wounds; application to bone surfaces to which prosthetic materials are attached with methylmethacrylate adhesives",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F196365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pain/numbness/paralysis: Pain, numbness, or paralysis have been reported if used near a bony or neural space and left inside patient; use minimum amount necessary to achieve hemostasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Remove as much of agent as possible after hemostasis is achieved. Do not leave in a contaminated or infected space. Fragments of MCH may pass through filters of blood scavenging systems; avoid reintroduction of blood from operative sites treated with MCH. Not intended to treat systemic coagulation disorders. Not for use when origin of bleeding is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F196369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F196364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Collagen hemostat is an absorbable topical hemostatic agent prepared from purified bovine corium collagen and shredded into fibrils. Physically, microfibrillar collagen hemostat yields a large surface area. Chemically, it is collagen with hydrochloric acid noncovalently bound to some of the available amino groups in the collagen molecules. When in contact with a bleeding surface, collagen hemostat attracts platelets which adhere to its fibrils and undergo the release phenomenon. This triggers aggregation of the platelets into thrombi in the interstices of the fibrous mass, initiating the formation of a physiologic platelet plug.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F196376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of hemostasis: 2-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &ge;8 weeks",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8507 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-49D3304717-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40258=[""].join("\n");
var outline_f39_20_40258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196383\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196390\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196384\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196385\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196373\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196361\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196374\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196395\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196388\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196377\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196365\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299089\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196369\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196364\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196376\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8507\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8507|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_20_40259="Piperacillin and tazobactam sodium: Patient drug information";
var content_f39_20_40259=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Piperacillin and tazobactam sodium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     see \"Piperacillin and tazobactam sodium: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/27/28086?source=see_link\">",
"     see \"Piperacillin and tazobactam sodium: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zosyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      AJ-PIP/TAZ;",
"     </li>",
"     <li>",
"      Piperacillin and Tazobactam for Injection;",
"     </li>",
"     <li>",
"      Tazocin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702747",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to piperacillin, tazobactam sodium, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store closely.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11250 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40259=[""].join("\n");
var outline_f39_20_40259=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210401\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210402\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015596\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015595\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015600\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015601\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015603\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015598\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015599\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015604\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015605\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=related_link\">",
"      Piperacillin and tazobactam sodium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/27/28086?source=related_link\">",
"      Piperacillin and tazobactam sodium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_20_40260="Acute eponychia";
var content_f39_20_40260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute eponychia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute eponychia is an infection of the proximal nail fold. This patient has an acute paronychia of the lateral nail fold in addition to an acute infection of the eponychium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40260=[""].join("\n");
var outline_f39_20_40260=null;
var title_f39_20_40261="Pathogenesis of tissue injury in glomerulonephritis";
var content_f39_20_40261=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of tissue injury in glomerulonephritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/20/40261/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/20/40261/contributors\">",
"     William G Couser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/20/40261/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/20/40261/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/20/40261/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/20/40261/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/20/40261/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large body of clinical, immunopathologic, and experimental data support the thesis that most forms of human glomerulonephritis (GN) result from immunologic mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. The etiologic agents in human GN are largely unknown with the exception of infectious agents, such as beta streptococci in poststreptococcal GN, or hepatitis C virus in cryoglobulinemic membranoproliferative glomerulonephritis (MPGN). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/14/41193?source=see_link\">",
"     \"Group A streptococcus: Virulence factors and pathogenic mechanisms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is likely that most precipitating factors, such as infections, and drug and toxin exposures, initiate similar immune responses that result in GN via shared common pathways. The nature of the immune responses which lead to GN, and the individuals who develop them, are strongly influenced by immunogenetic phenotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis of tissue injury in glomerulonephritis. The operative mechanisms of immune injury in GN are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=see_link\">",
"     \"Mechanisms of immune injury of the glomerulus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strong evidence exists that most human glomerulonephritides are forms of autoimmune disease. As a result, many etiologic agents likely cause GN by inducing loss of tolerance to self-antigens, and mechanisms like epitope spreading and molecular mimicry, rather than via a direct immune response to a foreign etiologic agent, such as observed experimentally with serum sickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nephritogenic immune response exhibits both humoral and cellular components. The humoral, or T helper cell 2(Th2)-regulated, immune response leads to immunoglobulin deposition formation and complement activation in glomeruli. The cellular, or T helper cell 1(Th1)-regulated, immune response contributes to the infiltration of glomeruli by circulating mononuclear inflammatory cells (including lymphocytes and macrophages) and crescent formation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43448?source=see_link\">",
"     \"Mechanisms of glomerular crescent formation\"",
"    </a>",
"    .) The basic events which link these components of the immune response to clinical glomerular injury are depicted schematically in the figure (",
"    <a class=\"graphic graphic_figure graphicRef52652 \" href=\"mobipreview.htm?5/47/5887\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Both humoral and cell-mediated immune processes trigger the local release of a host of inflammatory mediators. These mediators are responsible for producing the functional (primarily an increase in protein filtration and decrease in glomerular filtration rate) and structural (hypercellularity, necrosis, thrombosis, crescents and sclerosis) features that characterize the clinical and histologic appearance of GN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=see_link\">",
"     \"Mechanisms of immune injury of the glomerulus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Humoral immunity (Th 2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most human glomerular diseases are characterized by glomerular immunoglobulin deposition along with complement components, thereby suggesting that the humoral immune response is the principal cause of injury. Examples include post-infectious GN, IgA nephropathy, anti-glomerular basement membrane antibody disease, lupus nephritis, membranous nephropathy, Type 1 membranoproliferative GN, and some forms of rapidly progressive GN.",
"   </p>",
"   <p>",
"    Immune deposits form in the glomerulus either actively, because the target antigen(s) is localized predominantly in this structure, or passively because of the role of the glomerulus in filtration. Antibodies which induce glomerular immune deposits may be directed against the following antigens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal constituents of the glomerulus, such as the Goodpasture antigen on the non-collagenous domain of the alpha-III chain of type IV collagen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4409?source=see_link\">",
"       \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-renal self antigens localized in glomeruli, such as DNA-nucleosome complexes in systemic lupus erythematosus (SLE) or abnormally glycosylated IgA in IgA nephropathy. These non-glomerular endogenous antigens localize in glomeruli as a consequence of passive trapping often via interaction with negatively charged sites on the glomerular capillary wall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/2,10,11\">",
"       2,10,11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"      </a>",
"      .) Antigens may be localized alone followed by antibody binding to form immune complexes (in situ immune complex formation), or they may be passively trapped as components of immune complexes formed in the circulation.",
"     </li>",
"     <li>",
"      Exogenous antigens or immune aggregates that localize in glomerular capillaries via charge affinity for glomerular structures, passive trapping, or local precipitation of macromolecular aggregates (eg, HCV antigen-containing cryoglobulins in hepatitis C virus-associated MPGN, and abnormally glycosylated IgA that self-aggregates or binds to fibronectin in IgA nephropathy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=see_link\">",
"       \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20233?source=see_link\">",
"       \"Pathogenesis of IgA nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The structural and functional consequences of immune deposit formation in glomeruli depend upon at least four factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The site at which deposits form [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/14-18\">",
"       14-18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Deposits in the glomerular mesangium (mesangial deposits) cause injury by inducing mesangial cell proliferation, phenotype change, mediator release, and mesangial matrix expansion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/14,19\">",
"       14,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Deposits of a similar composition on the inner surface of the capillary wall (subendothelial deposits) are nephritogenic by virtue of their ability to recruit and activate effector cells, primarily circulating neutrophils and macrophages through chemotactic, immune adherence, and leukocyte adhesion molecule mechanisms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. The endothelial response to injury is also important [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=see_link\">",
"       \"Mechanisms of immune injury of the glomerulus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subepithelial deposits (on the outer surface of the capillary wall), although they may contain similar antigens and antibodies to deposits elsewhere, induce no inflammation. This is because they form at a site inaccessible to circulating cells, and complement-derived chemotactic peptides are moved by filtration forces into the urinary space rather than toward the capillary lumen. Subepithelial deposits cause damage by injuring the podocyte [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/17,18,21\">",
"       17,18,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The biologic properties of the immunoglobulins that form the deposits. As an example, complement-fixing IgG subtypes, such as IgG1 and IgG3, cause more injury than antibodies that activate complement poorly (eg, IgA or IgG4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. This is also supported by the finding that, in a mouse model of chronic serum sickness, the presence of complement factor H markedly limited glomerular inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=see_link\">",
"       \"Overview and clinical assessment of the complement system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The mechanism by which the deposits are formed. When antigen-antibody interaction takes place within the glomerulus itself (in situ immune complex formation), the process results in local complement activation and is much more nephritogenic than the passive trapping of similar complexes preformed in the circulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/2,13,25\">",
"       2,13,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The amount of immune deposit formation that occurs. As an example, the greater the quantity of immune deposits formed, the more tissue injury is produced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Independent of where or how immune deposits form in glomeruli, there is little evidence that immunoglobulins themselves induce any significant tissue injury except for antibodies directed at some components of the podocyte slit pore diaphragm, which can induce proteinuria without inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/26\">",
"     26",
"    </a>",
"    ]. Rather, injury usually occurs as a consequence of the activation of effector cells and release of a variety of inflammatory mediators (",
"    <a class=\"graphic graphic_figure graphicRef52652 \" href=\"mobipreview.htm?5/47/5887\">",
"     figure 1",
"    </a>",
"    ). These mediators include products of complement activation, such as C5a and C5b-9, induced by the antibodies themselves, oxidants and proteases released by both inflammatory and resident glomerular cells, and a variety of other cytokines, growth factors and vasoactive agents, usually triggering receptor-mediated signaling processes that initiate a complex interplay of events ultimately resulting in the structural and functional abnormalities seen in immune glomerular diseases&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cellular immunity (Th 1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strong evidence also exists for a primary role for mononuclear cells, particularly lymphocytes and macrophages, in the absence of antibody deposition, in causing glomerular injury in diseases such as minimal change nephrotic",
"    <span class=\"nowrap\">",
"     syndrome/focal",
"    </span>",
"    segmental glomerulosclerosis and crescentic glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/6,31-33\">",
"     6,31-33",
"    </a>",
"    ]. Presumably, similar principles as identified with humoral processes with respect to the site and magnitude of damage apply with regard to injury induced by antigen-specific sensitized cell-mediated immune mechanisms; however, possible cellular mediated processes in the glomerulus are less defined. Some evidence also supports a role for T cells alone, including specific T cell subsets, and platelets in glomerular pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40261/abstract/6,32,34,35\">",
"     6,32,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most human glomerulonephritides (GN) are forms of autoimmune disease. Etiologic agents likely cause GN by inducing loss of tolerance to self-antigens, and initiating mechanisms like epitope spreading and molecular mimicry, rather than via a direct immune response to a foreign etiologic agent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The nephritogenic immune response exhibits both humoral and cellular components. The humoral, or T helper cell 2(Th2)-regulated immune response leads to immunoglobulin deposition formation and complement activation in glomeruli. The cellular, or T helper cell 1(Th1)-regulated immune response contributes to the infiltration of glomeruli by circulating mononuclear inflammatory cells and crescent formation. Both humoral and cell-mediated processes trigger the local release of inflammatory mediators, which produce the functional and structural features that characterize GN. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most human glomerular diseases, (including post-infectious GN, IgA nephropathy, anti-glomerular basement membrane antibody disease, lupus nephritis, membranous nephropathy, Type 1 membranoproliferative GN, and some forms of rapidly progressive GN) are characterized by glomerular immunoglobulin deposition along with complement components. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Humoral immunity (Th 2)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immune deposits form in the glomerulus either actively, because the target antigen(s) is localized predominantly in this structure, or passively because the glomerulus plays a role in filtration. Antibodies may be directed against normal constituents of the glomerulus, such as the Goodpasture antigen; non-renal self antigens that are localized in glomeruli, such as DNA-nucleosome complexes in systemic lupus erythematosus; or exogenous antigens or immune aggregates that localize in glomerular capillaries via charge affinity for glomerular structures, passive trapping, or local precipitation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Humoral immunity (Th 2)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The structural and functional consequences of immune deposit formation in glomeruli depend upon at least four factors. These include the site at which deposits form; the biologic properties of the deposit-forming immunoglobulins; the mechanism by which deposits are formed; and the magnitude of immune deposit formation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Humoral immunity (Th 2)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunoglobulins themselves rarely induce significant tissue injury; injury occurs as a consequence of the activation of effector cells and release of inflammatory mediators. Mediators include products of complement activation, such as C5a and C5b-9; oxidants and proteases released by inflammatory and resident glomerular cells; and a variety of cytokines, growth factors, procoagulant actions, and vasoactive agents that trigger receptor-mediated signaling processes resulting in structural and functional abnormalities. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Humoral immunity (Th 2)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mononuclear cells, particularly lymphocytes and macrophages, play a primary role in diseases such as minimal change nephrotic",
"      <span class=\"nowrap\">",
"       syndrome/focal",
"      </span>",
"      segmental glomerulosclerosis and crescentic glomerulonephritis. Some evidence also supports a role for T cells alone, including specific T cell subsets, and platelets in glomerular pathology. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cellular immunity (Th 1)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/1\">",
"      Mathieson PW. Glomerulonephritis. Semin Immunopathol 2007; 29:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/2\">",
"      Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 2005; 9:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/3\">",
"      Chadban SJ, Atkins RC. Glomerulonephritis. Lancet 2005; 365:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/4\">",
"      Tipping PG, Kitching AR. Glomerulonephritis, Th1 and Th2: what's new? Clin Exp Immunol 2005; 142:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/5\">",
"      Puri TS, Quigg RJ. The many effects of complement C3- and C5-binding proteins in renal injury. Semin Nephrol 2007; 27:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/6\">",
"      Kurts C, Heymann F, Lukacs-Kornek V, et al. Role of T cells and dendritic cells in glomerular immunopathology. Semin Immunopathol 2007; 29:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/7\">",
"      Kashtan C. Autotopes and allotopes. J Am Soc Nephrol 2005; 16:3455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/8\">",
"      Hudson BG. The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol 2004; 15:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/9\">",
"      Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/10\">",
"      Kalaaji M, Fenton KA, Mortensen ES, et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007; 71:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/11\">",
"      Su W, Madaio MP. Recent advances in the pathogenesis of lupus nephritis: autoantibodies and B cells. Semin Nephrol 2003; 23:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/12\">",
"      Stehman-Breen C, Johnson RJ. Hepatitis C virus-associated glomerulonephritis. Adv Intern Med 1998; 43:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/13\">",
"      Couser WG, Salant DJ. In situ immune complex formation and glomerular injury. Kidney Int 1980; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/14\">",
"      G&oacute;mez-Guerrero C, Hern&aacute;ndez-Vargas P, L&oacute;pez-Franco O, et al. Mesangial cells and glomerular inflammation: from the pathogenesis to novel therapeutic approaches. Curr Drug Targets Inflamm Allergy 2005; 4:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/15\">",
"      Tipping PG, Holdsworth SR. Cytokines in glomerulonephritis. Semin Nephrol 2007; 27:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/16\">",
"      Adler S, Brady HR. Cell adhesion molecules and the glomerulopathies. Am J Med 1999; 107:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/17\">",
"      Salant DJ, Adler S, Darby C, et al. Influence of antigen distribution on the mediation of immunological glomerular injury. Kidney Int 1985; 27:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/18\">",
"      Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005; 16:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/19\">",
"      Moura IC, Benhamou M, Launay P, et al. The glomerular response to IgA deposition in IgA nephropathy. Semin Nephrol 2008; 28:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/20\">",
"      Mackinnon B, Deighan CJ, Ferrell WR, et al. Endothelial function in patients with proteinuric primary glomerulonephritis. Nephron Clin Pract 2008; 109:c40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/21\">",
"      Mathieson PW. Minimal change nephropathy and focal segmental glomerulosclerosis. Semin Immunopathol 2007; 29:415.",
"     </a>",
"    </li>",
"    <li>",
"     Madaio, MP, Foster, MH. Molecular structure and expression of nephritogenic autoantibodies in immune renal diseases. In: Immunologic Renal Diseases, 2nd ed, Neilson, EG, Couser, WG (Eds), Lippincott Williams &amp; Wilkins Publishers, Philadelphia 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/23\">",
"      Inal JM, Pascual M, Lesavre P, Schifferli JA. Complement inhibition in renal diseases. Nephrol Dial Transplant 2003; 18:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/24\">",
"      Alexander JJ, Pickering MC, Haas M, et al. Complement factor h limits immune complex deposition and prevents inflammation and scarring in glomeruli of mice with chronic serum sickness. J Am Soc Nephrol 2005; 16:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/25\">",
"      Quigg RJ. Why study membranous nephropathy in rats? Kidney Int 2003; 64:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/26\">",
"      Holth&ouml;fer H. Molecular architecture of the glomerular slit diaphragm: lessons learnt for a better understanding of disease pathogenesis. Nephrol Dial Transplant 2007; 22:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/27\">",
"      Couser WG. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant 1998; 13 Suppl 1:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/28\">",
"      Couser WG. Mediation of immune glomerular injury. J Am Soc Nephrol 1990; 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/29\">",
"      Couser WG. Mechanisms of glomerular injury in immune-complex disease. Kidney Int 1985; 28:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/30\">",
"      Anders HJ, Frink M, Linde Y, et al. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 2003; 170:5658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/31\">",
"      Kluth DC, Erwig LP, Rees AJ. Multiple facets of macrophages in renal injury. Kidney Int 2004; 66:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/32\">",
"      Ikezumi Y, Kanno K, Karasawa T, et al. The role of lymphocytes in the experimental progressive glomerulonephritis. Kidney Int 2004; 66:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/33\">",
"      Tipping PG, Holdsworth SR. T cells in glomerulonephritis. Springer Semin Immunopathol 2003; 24:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/34\">",
"      Rosenkranz AR, Knight S, Sethi S, et al. Regulatory interactions of alphabeta and gammadelta T cells in glomerulonephritis. Kidney Int 2000; 58:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40261/abstract/35\">",
"      Tanaka T, Kuroiwa T, Ikeuchi H, et al. Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40/CD40 ligand pathway and may amplify glomerular injury. J Am Soc Nephrol 2002; 13:2488.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3076 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40261=[""].join("\n");
var outline_f39_20_40261=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Humoral immunity (Th 2)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cellular immunity (Th 1)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3076\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3076|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/47/5887\" title=\"figure 1\">",
"      Mechanisms of glomerular damage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/14/41193?source=related_link\">",
"      Group A streptococcus: Virulence factors and pathogenic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43448?source=related_link\">",
"      Mechanisms of glomerular crescent formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=related_link\">",
"      Mechanisms of immune injury of the glomerulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4409?source=related_link\">",
"      Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20233?source=related_link\">",
"      Pathogenesis of IgA nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_20_40262="Methohexital: Pediatric drug information";
var content_f39_20_40262=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methohexital: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?24/15/24823?source=see_link\">",
"    see \"Methohexital: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/4/17476?source=see_link\">",
"    see \"Methohexital: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Brevital&reg; Sodium",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Brevital&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Barbiturate",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       General Anesthetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/15/24823?source=see_link\">",
"      see \"Methohexital: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses must be titrated to effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manufacturer's recommendations: Infants &ge;1 month and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Induction: 6.6-10 mg/kg of a 5% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: Induction: Usual: 25 mg/kg of a 1% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternative pediatric dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: Preoperative: 5-10 mg/kg/dose of a 5% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Induction: 1-2 mg/kg/dose of a 1% solution (Bj&ouml;rkman, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Procedural sedation: Initial: 0.5 mg/kg of a 1% solution given immediately prior to procedure; titrate dose to achieve level of sedation as needed, in increments of 0.5 mg/kg to a maximum dose of 2 mg/kg;",
"     <b>",
"      Note:",
"     </b>",
"     In the prospective phase of a study, 20 children (mean age: 26 months) undergoing emergency CT scans required a mean dose of 1 &plusmn; 0.5 mg/kg/dose with a mean total dose of 14 &plusmn; 7.5 mg/kg (Sedik, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rectal: Preoperative, anesthesia induction, or preprocedural: Usual: 25 mg/kg/dose; range: 20-35 mg/kg/dose; maximum dose: 500 mg/dose; give as 10% (100 mg/mL) aqueous solution 5-15 minutes prior to procedure (Bjorkman, 1987; Pomeranz, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Induction: Range: 1-1.5 mg/kg or 50-120 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: Intermittent I.V. bolus injection: 20-40 mg (2-4 mL of a 1% solution) every 4-7 minutes",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brevital&reg; Sodium: 500 mg, 2.5 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F194501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Reconstitute with NS to a maximum concentration of 50 mg/mL (5% solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bolus: Dilute with SWI (preferred), NS, or D",
"     <sub>",
"      5",
"     </sub>",
"     W to a maximum concentration of 10 mg/mL (1% solution); for induction, infuse a 1% solution at a rate of 1 mL/5 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous infusion: Dilute with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS to prepare a 0.2% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: Dilute with acceptable diluent to a recommended concentration of 10 mg/mL (1% solution);",
"     <b>",
"      Note:",
"     </b>",
"     10% solution has been given rectally (Bjorkman, 1987; Pomeranz, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F194505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Solutions are alkaline (pH 9.5-11) and",
"     <b>",
"      incompatible",
"     </b>",
"     with acids (eg, atropine sulfate, succinylcholine, silicone); also",
"     <b>",
"      incompatible",
"     </b>",
"     with phenol-containing solutions and silicone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Fenoldopam",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Atropine, glycopyrrolate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store vials at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Solutions should be freshly prepared and used promptly. Reconstituted solutions are chemically stable at room temperature for 24 hours; 0.2% (2 mg/mL) solutions in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS are stable at room temperature for 24 hours.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Do not dilute with solutions containing bacteriostatic agents; acceptable diluents: D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, SWI, or accompanying diluent (for 500 mg vial to make a 1% solution); SWI is the preferred diluent except for making the 0.2% solution for I.V. continuous infusion (use of SWI to make the 0.2% solution will result in extreme hypotonicity; D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS should be used); dilute with D",
"     <sub>",
"      5",
"     </sub>",
"     W for I.V. or rectal administration only (not for I.M. use). Do not use I.V./I.M. solutions if not clear and colorless. Solutions are alkaline (pH 9.5-11) and incompatible with acids (eg, atropine sulfate, succinylcholine chloride); incompatible with phenol-containing solutions, silicone, and LR",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induction of anesthesia prior to the use of other general anesthetic agents (I.M., rectal: FDA approved in ages &gt;1 month; I.V.: FDA approved in adults); adjunct to subpotent inhalational anesthetic agents for short surgical procedures (I.M., rectal: FDA approved in ages &gt;1 month; I.V.: FDA approved in adults); anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli (I.M., rectal: FDA approved in ages &gt;1 month; I.V.: FDA approved in adults); anesthesia for use with other parenteral agents, usually narcotic analgesics, to supplement subpotent inhalational anesthetic agents for longer surgical procedures (FDA approved in adults); induction of hypnotic state (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Brevital&reg; may be confused with Brevibloc&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F194504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiorespiratory arrest, circulatory depression, hypotension, peripheral vascular collapse, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, emergence delirium, headache, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea, salivation, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain, nerve injury adjacent to injection site, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Involuntary muscle movement, radial nerve palsy, rigidity, tremor, twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, bronchospasm, cough, dyspnea, hiccups, laryngospasm, respiratory depression, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methohexital, barbiturates, or any component; porphyria; patients in whom general anesthesia is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution in patients with liver impairment, asthma, cardiovascular instability; may precipitate seizures in patients with history of convulsions, especially partial seizure disorders; prolonged administration may result in increased CNS, respiratory, and cardiovascular effects; use with caution in patients with obstructive pulmonary disease, severe hypertension or hypotension, myocardial disease, CHF, severe anemia, extreme obesity, renal impairment, or endocrine disorders. Safety and efficacy of I.V. administration in pediatric patients have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuously monitor respiratory function, pulse oximetry, and cardiac function. Resuscitative drugs, ventilation and intubation equipment, and trained personnel should be immediately available",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . For deep sedation, a designated individual (other than the person performing the procedure) should be present to continuously monitor the patient. Prior to I.V. administration, ensure patient has adequate I.V. access; extravasation or intra-arterial injection causes necrosis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Barbiturates may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Barbiturates may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Barbiturates may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Barbiturates may increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Barbiturates may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Barbiturates may decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: Barbiturates may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates.  Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Barbiturates may enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Barbiturates may enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Barbiturates may enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Barbiturates may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Barbiturates may enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6743972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not shown fetal or maternal harm. There are no adequate and well-controlled studies in pregnant women. Methohexital crosses the placenta. Use only if potential benefit outweighs risk to fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, respiratory rate, oxygen saturation, pulse oximetry",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ultra short-acting I.V. barbiturate anesthetic; depresses CNS activity by binding to barbiturate site at GABA-receptor complex enhancing GABA activity; depresses reticular activating system; higher doses may be gabamimetic",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (pediatric patients): 2-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 1 minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal (pediatric patients): 5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 7-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: 1-1.5 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver via demethylation and oxidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Rectal: 17%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Through the kidney via glomerular filtration",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/4/17476?source=see_link\">",
"      see \"Methohexital: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; do not drive a motor vehicle or operate machinery until 8-12 hours after medication was administered, or until normal functions return (whichever is longer)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Does not possess analgesic properties; Brevital&reg; has FDA-approved labeling for I.V. use in adults, and for rectal and I.M. use only in pediatric patients &gt;1 month of age; 100 pediatric patients (3 months to 5 years of age) received rectal methohexital (25 mg/kg) for sedation prior to computed tomography (CT) scan; sedation was adequate in 95% of patients; mean time for full sedation = 8.2 &plusmn; 3.9 minutes; mean duration of action = 79.3 &plusmn; 30.9 minutes; 10% of patients had transient side effects (Pomeranz, 2000)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bj&ouml;rkman S, Gabrielsson J, Quaynor H, et al, \"Pharmacokinetics of I.V. and Rectal Methohexitone in Children,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1987, 59(12):1541-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40262/abstract-text/3426908/pubmed\" id=\"3426908\" target=\"_blank\">",
"        3426908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cot&eacute; CJ, \"Sedation for the Pediatric Patient,\"",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1994, 41(1):31-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40262/abstract-text/8295806/pubmed\" id=\"8295806\" target=\"_blank\">",
"        8295806",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elman DS and Denson JS, \"Preanesthetic Sedation of Children With Intramuscular Methohexital Sodium,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1965, 44(5):494-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40262/abstract-text/5890378/pubmed\" id=\"5890378\" target=\"_blank\">",
"        5890378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller JR, Grayson M, and Stoelting VK, \"Sedation With Intramuscular Methohexital Sodium for Office and Clinic Ophthalmic Procedures in Children,\"",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 1966, 62(1):38-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40262/abstract-text/5936524/pubmed\" id=\"5936524\" target=\"_blank\">",
"        5936524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pomeranz ES, Chudnofsky CR, Deegan TJ, et al, &ldquo;Rectal Methohexital Sedation for Computed Tomography Imaging of Stable Pediatric Emergency Department Patients,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 105(5):1110-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40262/abstract-text/10790471/pubmed\" id=\"10790471\" target=\"_blank\">",
"        10790471",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sedik H, \"Use of Intravenous Methohexital as a Sedative in Pediatric Emergency Departments,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2001, 155(6):665-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40262/abstract-text/11386953/pubmed\" id=\"11386953\" target=\"_blank\">",
"        11386953",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12594 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.211.0.116-9E1753412A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40262=[""].join("\n");
var outline_f39_20_40262=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709039\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194470\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194471\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053891\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053883\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194457\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194441\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194501\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053896\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194505\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053886\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053895\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194506\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194504\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053900\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053882\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053881\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299690\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194450\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194452\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6743972\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053890\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053880\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053898\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053899\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053888\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053901\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12594\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12594|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/15/24823?source=related_link\">",
"      Methohexital: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/4/17476?source=related_link\">",
"      Methohexital: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_20_40263="Oseltamivir: Drug information";
var content_f39_20_40263=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oseltamivir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/16/1285?source=see_link\">",
"    see \"Oseltamivir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/59/18360?source=see_link\">",
"    see \"Oseltamivir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15845441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Expanded Pediatric Use for Oseltamivir (Tamiflu&reg;)",
"     </span>",
"     <span class=\"collapsible-date\">",
"      December 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) has expanded the use of oseltamivir (Tamiflu&reg;) for the treatment of influenza in children as young as 2 weeks old who have shown symptoms of influenza for &le;2 days. Previously, Tamiflu&reg; was only FDA approved for influenza treatment in children &ge;1 year of age.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Recommended dosing for influenza treatment in children &lt;1 year is 3 mg/kg twice daily for 5 days which requires that each dose be calculated using the child&rsquo;s exact weight. In addition, these smaller doses will require that the pharmacist provide a proper dosing device so that parents can accurately measure and administer the correct dose. The dosing device that is currently packaged with Tamiflu&reg; powder for oral suspension will not accurately measure the dose and should not be used for children &lt;1 year of age.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, see",
"       <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333205.htm?source=govdelivery\" target=\"_blank\">",
"        file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333205.htm?source=govdelivery",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tamiflu&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tamiflu&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F204138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent;",
"     </li>",
"     <li>",
"      Neuraminidase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F204118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Influenza prophylaxis:",
"     </b>",
"     Oral: 75 mg once daily; initiate prophylaxis within 48 hours of contact with an infected individual; duration of prophylaxis: 10 days (manufacturer recommendation) or alternatively 7 days (CDC, 2012).  During community outbreaks, duration of protection lasts for length of dosing period; safety and efficacy have been demonstrated for use up to 6 weeks in immunocompetent patients and safety has been demonstrated for use up to 12 weeks in patients who are immunocompromised.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis (institutional outbreak; CDC, 2012):",
"     </i>",
"     Continue for &ge;2 weeks and until ~7 days after identification of illness onset in the last patient",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Influenza treatment:",
"     </b>",
"     Oral: 75 mg twice daily initiated within 48 hours of onset of symptoms; duration of treatment: 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Hospitalized patients with severe influenza infection may require longer (eg, &ge;10 days) treatment courses. Some experts also recommend empirically doubling the treatment dose. Initiate as early as possible in any hospitalized patient with suspected/confirmed influenza (CDC, 2011); may be administered via naso- or orogastric tube in mechanically-ventilated patients (Taylor, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F204130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/59/18360?source=see_link\">",
"      see \"Oseltamivir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Influenza prophylaxis:",
"     </b>",
"     Oral: Initiate prophylaxis within 48 hours of contact with an infected individual",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s recommendation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 1-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;15 kg: 30 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;15 kg to &le;23 kg: 45 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;23 kg to &le;40 kg: 60 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;40 kg: 75 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &ge;13 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternate recommendations:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 3-11 months (unlabeled dosing; AAP, 2010):",
"     <b>",
"      Note:",
"     </b>",
"     Dosing based on age (use only if weight not available)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     3-5 months: 20 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-11 months: 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;12 months (unlabeled dosing, CDC, 2012):",
"     <b>",
"      Note:",
"     </b>",
"     Prophylaxis is not recommended for infants &lt;3 months of age unless clinically critical; weight-based dosing recommendations are not intended for premature neonates: 3 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 3-23 months (unlabeled dosing, IDSA/PIDS, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     3-8 months: 3 mg/kg/dose once daily (do not exceed maximum dose of weight-based dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     9-23 months: 3.5 mg/kg/dose once daily (do not exceed maximum dose of weight-based dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Prophylaxis duration:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Individual/household exposure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Alternate recommendations:",
"     </i>",
"     7 days (CDC, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Community/institutional outbreak:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     May be used for up to 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Alternate recommendations:",
"     </i>",
"     Continue for &ge;2 weeks and until ~7 days after identification of illness onset in the last patient (CDC, 2012) or until influenza activity in community subsides or immunity obtained from immunization (IDSA/PIDS, 2011). During community outbreaks, duration of protection lasts for length of dosing period; safety and efficacy have been demonstrated for use up to 6 weeks in immunocompetent patients and safety has been demonstrated for use up to 12 weeks in patients who are immunocompromised.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Influenza treatment:",
"     </b>",
"     Oral: Initiate treatment within 48 hours of onset of symptoms; duration of treatment: 5 days unless severely ill and hospitalized.",
"     <b>",
"      Note:",
"     </b>",
"     Hospitalized patients may require longer (eg, &ge;10 days) treatment courses. Some experts also recommend empirically doubling the treatment dose. Doubling the dose in adult outpatients was not associated with increased adverse events. As no double-dose studies have been published in children, use caution. Initiate as early as possible in any hospitalized patient with suspected/confirmed influenza (CDC, 2011); may be administered via naso- or orogastric tube in mechanically-ventilated patients (Taylor, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s recommendation:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     The following dosing is also supported by some clinicians (IDSA/PIDS, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &ge;2 weeks: 3 mg/kg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 1-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;15 kg: 30 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;15 kg to &le;23 kg: 45 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;23 kg to &le;40 kg: 60 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;40 kg: 75 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &ge;13 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternate recommendations:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;2 weeks (unlabeled dosing, CDC, 2012):",
"     <b>",
"      Note:",
"     </b>",
"     Weight-based dosing recommendations are not intended for premature neonates: 3 mg/kg/dose twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;12 months (unlabeled dosing; AAP, 2010):",
"     <b>",
"      Note:",
"     </b>",
"     Dosing based on age (use only if weight not available):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;3 months: 12 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     3-5 months: 20 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-11 months: 25 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children &lt;24 months (unlabeled dosing; IDSA/PIDS, 2011):",
"     <b>",
"      Note:",
"     </b>",
"     Do not exceed maximum dose of weight-based dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants, premature: 1 mg/kg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     0-8 months: 3 mg/kg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     9-23 months: 3.5 mg/kg/dose twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F204119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F204120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: 75 mg once daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30-60 mL/minute: 30 mg twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: 30 mg once daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     High-dose treatment (unlabeled [eg, severely-ill hospitalized patients with 2009 H1N1 influenza]): Currently no data are available; consider 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prophylaxis: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: 75 mg every other day or 30 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30-60 mL/minute: 30 mg once daily for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: 30 mg every other day for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CAPD: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unlabeled dose: 30 mg once weekly (Robson, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling (not in U.S. labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: 30 mg prior to start of dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: 30 mg prior to start of dialysis, then 30 mg every 7 days for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;1 year (unlabeled dose; Schreuder, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;15 kg: 7.5 mg after each hemodialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;15 kg to &le;23 kg: 10 mg after each hemodialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;23 kg to &le;40 kg: 15 mg after each hemodialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;40 kg: 30 mg after each hemodialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Unlabeled dose: 30 mg after every other session (Robson, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Canadian labeling (not in U.S. labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Treatment: 30 mg prior to dialysis;  if symptomatic between dialysis sessions, then administer 30 mg after each dialysis session over period of 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Prophylaxis: 30 mg prior to dialysis, then 30 mg after every other dialysis session for period of 10-14 days",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F204121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: Pharmacokinetics and safety  have not been evaluated",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as phosphate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tamiflu&reg;: 30 mg, 45 mg, 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tamiflu&reg;: 6 mg/mL (60 mL) [contains sodium benzoate; tutti frutti flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5383845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals; take with food to improve tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsules may be opened and mixed with sweetened liquid (eg, chocolate syrup). Administer oral suspension using the supplied oral syringe (exception: for children &lt;1 year, a smaller volume [ie, &lt;10 mL] oral syringe should be used in place of the supplied oral syringe to ensure accurate dosing); shake well.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mechanically-ventilated critically-ill patients: May administer via naso- or orogastric (NG/OG) tube. For a 150 mg dose, dissolve powder from two 75 mg capsules in 20 mL of sterile water and inject down the NG/OG tube; follow with a 10 mL sterile water flush (Taylor, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F204092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of uncomplicated acute illness due to influenza (A or B) infection in children &ge;2 weeks and adults who have been symptomatic for no more than 2 days; prophylaxis against influenza (A or B) infection in children &ge;1 year of age and adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends that",
"     <b>",
"      treatment",
"     </b>",
"     be considered for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Persons with severe, complicated or progressive illness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hospitalized persons",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Persons at higher risk for influenza complications:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Children &lt;2 years of age (highest risk in children &lt;6 months of age)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - 	Adults &ge;65 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Persons with chronic disorders of the pulmonary (including asthma) or cardiovascular systems (except hypertension)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Persons with chronic metabolic diseases (including diabetes mellitus), hepatic disease, renal dysfunction, hematologic disorders (including sickle cell disease), or immunosuppression (including immunosuppression caused by medications or HIV)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     -	Persons with neurologic/neuromuscular conditions (including conditions such as spinal cord injuries, seizure disorders, cerebral palsy, stroke, mental retardation, moderate to severe developmental delay, or muscular dystrophy) which may compromise respiratory function, the handling of respiratory secretions, or that can increase the risk of aspiration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Pregnant or postpartum women (&le;2 weeks after delivery)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     -	Persons &lt;19 years of age on long-term aspirin therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - American Indians and Alaskan Natives",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - 	Persons who are morbidly obese (BMI &ge;40)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Residents of nursing homes or other chronic care facilities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Use may also be considered for previously healthy, nonhigh-risk outpatients with confirmed or suspected influenza based on clinical judgment when treatment can be started within 48 hours of illness onset.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     The ACIP recommends that",
"     <b>",
"      prophylaxis",
"     </b>",
"     be considered for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Postexposure prophylaxis may be considered for family or close contacts of suspected or confirmed cases, who are at higher risk of influenza complications, and who have not been vaccinated against the circulating strain at the time of the exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Postexposure prophylaxis may be considered for unvaccinated healthcare workers who had occupational exposure without protective equipment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Pre-exposure prophylaxis should only be used for persons at very high risk of influenza complications who cannot be otherwise protected at times of high risk for exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Prophylaxis should also be administered to all eligible residents of institutions that house patients at high risk when needed to control outbreaks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     The ACIP recommends that treatment and prophylaxis be given to children &lt;1 year of age when indicated.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F204146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tamiflu&reg; may be confused with Tambocor&trade;, Thera-Flu&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oseltamivir (Tamiflu&reg;) oral suspension is available in a 6 mg/mL concentration and is packaged with an oral syringe calibrated in",
"       <b>",
"        milliliters",
"       </b>",
"       up to a total of 10 mL.",
"       <b>",
"        Instructions to the patient should be provided based on these units of measure (ie, mL). When providing oseltamivir suspension for children &lt;1 year of age, use a lower calibrated (ie, &lt;10 mL) oral syringe to ensure accurate dosing.",
"       </b>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"       When commercially-prepared oseltamivir oral suspension is not available, an extemporaneously prepared suspension may be compounded to provide a 6 mg/mL concentration.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F204136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Gastrointestinal: Vomiting (2% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (4% to 10%), abdominal pain (2% to 5%), diarrhea (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Conjunctivitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Epistaxis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergy, anaphylactic/anaphylactoid reaction, angina, arrhythmia, confusion, erythema multiforme, fracture, gastrointestinal bleeding, hemorrhagic colitis, hepatitis, liver function tests abnormal, neuropsychiatric events, pseudomembranous colitis, pyrexia, seizure, Stevens-Johnson syndrome, swelling of face or tongue, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F204096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oseltamivir or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F204081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity: Rare but severe hypersensitivity reactions (anaphylaxis, severe dermatologic reactions) have been associated with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric events: Rare occurrences of neuropsychiatric events (including confusion, delirium, hallucinations, and/or self-injury) have been reported primarily in pediatric patients from postmarketing surveillance; direct causation is difficult to establish (influenza infection may also be associated with behavioral and neurologic changes). Monitor closely for signs of any unusual behavior.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with chronic cardiac disease; efficacy has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment is required for creatinine clearance &lt;30 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease; efficacy has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunocompromised patients: Use with caution in immunocompromised patients; safety and efficacy for treatment or prophylaxis in immunocompromised patients have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Oseltamivir is not a substitute for the influenza virus vaccine. It has not been shown to prevent primary or concomitant bacterial infections that may occur with influenza virus. Antiviral treatment should begin within 48 hours of symptom onset. However, the CDC recommends that treatment may still be beneficial and should be started in hospitalized patients with severe, complicated or progressive illness if &gt;48 hours. Treatment should not be delayed while awaiting results of laboratory tests for influenza. Nonhospitalized persons who are not at high risk for developing severe or complicated illness and who have a mild disease are not likely to benefit if treatment is started &gt;48 hours after symptom onset. Nonhospitalized persons who are already beginning to recover do not need treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase serum concentrations of the active metabolite(s) of Oseltamivir. Management: Consider a change in therapy when using oseltamivir together with probenecid; reduced oseltamivir dose may be necessary.  Increase monitoring for adverse events, such as thrombocytopenia.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In animal reproduction studies, a dose-dependent increase in the rates of minor skeleton abnormalities was found in exposed offspring. The rate of each abnormality remained within the background rate of occurrence in the species studied. Oseltamivir phosphate and its active metabolite oseltamivir carboxylate cross the placenta (",
"     <i>",
"      in vitro",
"     </i>",
"     data). An increased risk of adverse neonatal outcomes has generally not been observed following maternal use of oseltamivir during pregnancy. Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Oseltamivir and zanamivir are currently recommended for the treatment or prophylaxis of influenza in pregnant women and women up to 2 weeks postpartum. Oseltamivir and zanamivir are currently recommended as an adjunct to vaccination and should not be used as a substitute for vaccination in pregnant women (consult current CDC guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F204123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F204100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of oseltamivir and oseltamivir carboxylate have been detected in breast milk. Breast-feeding is not recommended by the manufacturer. According to the CDC, breast-feeding while taking oseltamivir can be continued. The CDC recommends that women infected with the influenza virus follow general precautions (eg, frequent hand washing) to decrease viral transmission to the child. Mothers with influenza-like illnesses at delivery should consider avoiding close contact with the infant until they have received 48 hours of antiviral medication, fever has resolved, and cough and secretions can be controlled. These measures may help decrease (but not eliminate) the risk of transmitting influenza to the newborn. During this time, breast milk can be expressed and bottle-fed to the infant by another person who is well. Protective measures, such as wearing a face mask, changing into a clean gown or clothing, and strict hand hygiene should be continued by the mother for &ge;7 days after the onset of symptoms or until symptom-free for 24 hours. Infant care should be performed by a noninfected person when possible (consult current CDC guidelines). Influenza may cause serious illness in postpartum women and prompt evaluation for febrile respiratory illnesses is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F204101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take without regard to meals; take with food to improve tolerance.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F204098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Tamiflu Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (10): $111.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (10): $111.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (10): $121.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Tamiflu Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/mL (60 mL): $121.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3467518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs or symptoms of unusual behavior, including attempts at self-injury, confusion, and/or delirium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Critically-ill patients: Repeat rRT-PCR or viral culture may help to determine on-going viral replication",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F204102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ao Er Fei (CL);",
"     </li>",
"     <li>",
"      GPO-A-Flu (TH);",
"     </li>",
"     <li>",
"      Omiflu (MY);",
"     </li>",
"     <li>",
"      Tamiflu (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, HU, IE, IL, IT, JP, KP, MT, MX, NL, NO, NZ, PE, PH, PK, PL, PT, PY, RU, SE, SG, SK, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F204080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oseltamivir, a prodrug, is hydrolyzed to the active form, oseltamivir carboxylate (OC). OC inhibits influenza virus neuraminidase, an enzyme known to cleave the budding viral progeny from its cellular envelope attachment point (neuraminic acid) just prior to release.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F204095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 23-26 L (oseltamivir carboxylate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: Oseltamivir carboxylate: 3%; Oseltamivir: 42%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (90%) to oseltamivir carboxylate; neither the parent drug nor active metabolite has any effect on the cytochrome P450 system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 75% as oseltamivir carboxylate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oseltamivir: 1-3 hours; Oseltamivir carboxylate: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&gt;90% as oseltamivir carboxylate); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Infectious Diseases, &ldquo;Policy, Statement -- Recommendations for Prevention and Control of influenza in Children, 2010-2011,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(4):816-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40263/abstract-text/20805143/pubmed\" id=\"20805143\" target=\"_blank\">",
"        20805143",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aoki FY, Allen UD, Stiver HG, et al, AMMI Canada Guidelines, \"The Use of Antiviral Drugs for Influenza: Guidance for Practitioners 2012/2013,&rdquo;",
"      <i>",
"       Can J Infect Dis Med Microbiol",
"      </i>",
"      , 2012, 23(4):e79-92. Available at file://www.ammi.ca/media/48038/14791_aoki_final.pdf.pdf.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40263/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Intensive-Care Patients With Severe Novel Influenza A (H1N1) Virus Infection - Michigan, June 2009,&rdquo;",
"      <i>",
"       MMWR Morb  Mortal Wkly Rep",
"      </i>",
"      ,  2009, 58(27):749-52. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5827a4.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5827a4.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40263/abstract-text/19609249/pubmed\" id=\"19609249\" target=\"_blank\">",
"        19609249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Influenza Antiviral Medications: Summary for Clinicians.&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm\" target=\"_blank\">",
"       file://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm",
"      </a>",
"      . Accessed on November 26, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Influenza Division, National Center for Immunization and Respiratory Diseases. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza --- Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Surveill Summ",
"      </i>",
"      , 2011, 60(1):1-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40263/abstract-text/21248682/pubmed\" id=\"21248682\" target=\"_blank\">",
"        21248682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harper SA, Bradley JS, Englund JA, et al, &ldquo;Seasonal Influenza in Adults and Children--Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(8):1003-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40263/abstract-text/19281331/pubmed\" id=\"19281331\" target=\"_blank\">",
"        19281331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      He G, Massarella J, and Ward P, &ldquo;Clinical Pharmacokinetics of the Prodrug Oseltamivir and Its Active Metabolite Ro 64-0802,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1999, 37(6):471-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40263/abstract-text/10628898/pubmed\" id=\"10628898\" target=\"_blank\">",
"        10628898",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jain S, Kamimoto L, Bramley AM, et al, &ldquo;Hospitalized Patients With 2009 H1N1 Influenza in the United States, April-June 2009,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(20):1935-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40263/abstract-text/19815859/pubmed\" id=\"19815859\" target=\"_blank\">",
"        19815859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Okumura A, Kubota T, and Kato T, &ldquo;Oseltamivir and Delirious Behavior in Children With Influenza,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2006, 25(6):572.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robson R, Buttimore A, Lynn K, et al, &ldquo;The Pharmacokinetics and Tolerability of Oseltamivir Suspension in Patients on Haemodialysis and Continuous Ambulatory Peritoneal Dialysis,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2006, 21(9):2556-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40263/abstract-text/16799169/pubmed\" id=\"16799169\" target=\"_blank\">",
"        16799169",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schreuder MF, van der Flier M, Knops NB, et al, &ldquo;Oseltamivir Dosing in Children Undergoing Hemodialysis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(10):1427-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40263/abstract-text/20397934/pubmed\" id=\"20397934\" target=\"_blank\">",
"        20397934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor WRJ, Thinh BN, Anh GT, et al, &ldquo;Oseltamivir is Adequately Absorbed Following Nasogastric Administration to Adult Patients With Severe H5N1 Influenza,&rdquo;",
"      <i>",
"       PLoS One",
"      </i>",
"      , 2008, 3(10):e3410.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40263/abstract-text/18923671/pubmed\" id=\"18923671\" target=\"_blank\">",
"        18923671",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wentges-van Holthe N, van Eijkeren M, and van der Laan JW, &ldquo;Oseltamivir and Breastfeeding,&rdquo;",
"      <i>",
"       Int J Infect Dis",
"      </i>",
"      , 2008, 12(4):451.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/20/40263/abstract-text/18243025/pubmed\" id=\"18243025\" target=\"_blank\">",
"        18243025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9460 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40263=[""].join("\n");
var outline_f39_20_40263=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15845441\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204115\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204116\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204138\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204118\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204130\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204119\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204120\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204121\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204091\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204077\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5383845\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204092\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204146\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204136\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204096\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204081\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299796\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204086\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204088\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204099\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204123\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204100\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204101\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204098\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3467518\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204102\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204080\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204095\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9460\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9460|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/16/1285?source=related_link\">",
"      Oseltamivir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/59/18360?source=related_link\">",
"      Oseltamivir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_20_40264="Skin biopsy techniques";
var content_f39_20_40264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Skin biopsy techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/20/40264/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/20/40264/contributors\">",
"     Patrick C Alguire, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/20/40264/contributors\">",
"     Barbara M Mathes, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/20/40264/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/20/40264/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/20/40264/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/20/40264/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/20/40264/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 19, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin biopsy is a relatively simple but essential procedure in the management of skin disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/1\">",
"     1",
"    </a>",
"    ]. The most commonly performed biopsy procedures are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;More errors are made from failing to biopsy promptly than from performing unnecessary biopsies. Nevertheless, many dermatoses have nonspecific histopathology, and biopsy cannot substitute for good clinical skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Biopsy is indicated in the following circumstances (",
"    <a class=\"graphic graphic_table graphicRef67185 \" href=\"mobipreview.htm?17/63/18428\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      All suspected neoplastic lesions",
"     </li>",
"     <li>",
"      All bullous disorders",
"     </li>",
"     <li>",
"      To clarify a diagnosis when a limited number of entities are under consideration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Biopsy can also serve as the definitive treatment for irritated, inflamed, precancerous, or malignant lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ]. However, for malignant lesions, a pathologic report indicating that the biopsy margins are \"clear\" does not necessarily mean that there has been adequate therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Initial biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=see_link\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few absolute contraindications to skin biopsy. It usually should not be performed at an infected site, although occasionally infection is the indication for the procedure. Patients should be asked about allergies to topical antibiotics, antiseptics, local anesthetics, and reactions to tape.",
"   </p>",
"   <p>",
"    Inquiries also should be made regarding bleeding disorders, bleeding with previous surgery, and use of drugs known to interfere with hemostasis. Excessive bleeding is rarely a problem in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . Patients taking aspirin can generally be managed with careful attention to hemostasis and the use of a pressure dressing (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Hemostasis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Complications'",
"    </a>",
"    below). We suggest that patients on warfarin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    be referred to a dermatologist or surgeon for biopsies. These medications should generally not be discontinued for simple skin biopsies. We also suggest referral to a dermatologist or surgeon for biopsies in patients with bleeding disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SITE SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Site selection can be critical to diagnosis. The appropriate biopsy site depends upon the type of lesion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For inflammatory lesions, those with characteristic inflammatory changes (eg, erythema) should be biopsied first; evolutionary changes may take time so biopsies performed too early and very late lesions may reveal only nonspecific or secondary features [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/2-4,7-9\">",
"       2-4,7-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For blistering diseases, early evolving lesions have more specific histopathology and are preferred for biopsy. Only the newest vesicles and blisters should be biopsied, ideally within 48 hours of their appearance. Older lesions with secondary changes such as crusts, fissures, erosions, excoriations, and ulcerations should be avoided since the primary pathological process may be obscured.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The location of biopsy within a particular lesion also depends upon the type and size of the lesions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For nonbullous lesions, the biopsy should include maximal lesional skin and minimal normal skin. For lesions between 1 and 4 mm in diameter, biopsy the center or excise the entire lesion. For large lesions, biopsy the edge, the thickest portion, or the area that is most abnormal in color; these sites will most likely contain the distinctive pathology.",
"     </li>",
"     <li>",
"      Remove vesicles intact when possible, with adjacent normal appearing skin; disruption makes histologic interpretation more difficult.",
"     </li>",
"     <li>",
"      Bullae should be biopsied at the edge to include a small part of the blister with adjacent intact skin, keeping the blister roof attached. This technique is important for diagnosis; it allows the pathologist to determine the level of blister formation within the skin (eg, subcorneal, intraepidermal, subepidermal).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several sites should be biopsied if the differential diagnosis is broad to minimize sampling error.",
"   </p>",
"   <p>",
"    Important cosmetic areas such as the face and areas with poor healing characteristics (distal lower extremities) should be avoided if possible when choosing a biopsy site for a generalized process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/4,8,10\">",
"     4,8,10",
"    </a>",
"    ]. When there are individual suspicious lesions involving the face or other cosmetically important areas, it may be preferable to refer the patient to a dermatologist or plastic surgeon who has expertise in such biopsies.",
"   </p>",
"   <p>",
"    All biopsies leave scars. Hypertrophic scarring tends to occur over the deltoid and chest areas; delayed healing can be a problem over the tibia, especially in diabetic patients or in patients with arterial or venous insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/8\">",
"     8",
"    </a>",
"    ]. The incidence of secondary infection in the groin and axillae is high; biopsy these areas only if other sites are unavailable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BIOPSY TECHNIQUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shave and punch biopsies are clean, not sterile procedures; mask, gown, and sterile gloves are not necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/7\">",
"     7",
"    </a>",
"    ]. Mask, gown, and sterile gloves are indicated for excisions and are reasonable for any patient at increased risk of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/7\">",
"     7",
"    </a>",
"    ]. A list of the supplies and instruments necessary is shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef58432 \" href=\"mobipreview.htm?13/31/13820\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Preparing the site",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any common skin antiseptic such as isopropyl alcohol, povidone-iodine, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    can be used to prepare the biopsy site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/3,5,7\">",
"     3,5,7",
"    </a>",
"    ]. Mark the intended lesion with a surgical marker since it may be temporarily obliterated following injection of the anesthetic. Marking the outlines for excisional biopsies also can be helpful. For excisions, place a fenestrated surgical drape over the biopsy site after the area is cleansed and anesthetized.",
"   </p>",
"   <p>",
"    Round wounds tend to be pulled open in the direction of skin tension lines (known as Langer's lines) that generally parallel the direction of collagen in the dermis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Tension lines can be demonstrated by gently compressing relaxed skin with the thumb and index finger; wrinkle lines on the face are another good indicator. Surgical incisions placed parallel to tension lines will close more easily and cosmetically than those placed at right angles (",
"    <a class=\"graphic graphic_picture graphicRef79204 \" href=\"mobipreview.htm?40/16/41217\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/6,10-12\">",
"     6,10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used local anesthetic is 1 or 2 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . Small amounts of epinephrine are added to constrict blood vessels, decrease bleeding, prolong anesthesia, and limit lidocaine toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. The onset of vasoconstriction is about 10 minutes slower than that of anesthesia.",
"   </p>",
"   <p>",
"    Given the vasoconstrictive properties of epinephrine, concern has been raised regarding the possibility of epinephrine-induced ischemic necrosis in areas such as the digits, ears, and nose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/6,10,13\">",
"     6,10,13",
"    </a>",
"    ]. However, the results of some studies suggest that with proper technique, local infiltrative anesthesia with dilute solutions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with epinephrine may be safe for use in these areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following can minimize the sting of injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/3,5,11\">",
"     3,5,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mix 1 mL of NaHCO3 with 9 mL of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"     </li>",
"     <li>",
"      Use a 30-gauge needle",
"     </li>",
"     <li>",
"      Make the initial injection perpendicular (or near perpendicular) to the skin",
"     </li>",
"     <li>",
"      Deep injections sting less than superficial injections but prolong the time to adequate anesthesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Small syringes (1 and 3 cc) permit easier injections and are less cumbersome to handle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The anesthetic can be injected directly into or immediately adjacent to small lesions. The anesthetic must be infiltrated into the dermis if it is being used to elevated a lesion for biopsy. A field block should be performed for larger lesions by placing a ring of anesthetic around the surgical site, advancing and injecting through a site that has been previously anesthetized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/11,18\">",
"     11,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Choice of procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shave biopsies are quick, require little training, and do not require sutures for closure; a small depressed scar about the size of the initial lesion is likely to occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/19\">",
"     19",
"    </a>",
"    ]. Lesions that are most suitable for shave biopsies are either elevated above the skin or have pathology confined to the epidermis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/5,7,11,19\">",
"     5,7,11,19",
"    </a>",
"    ]. Examples include seborrheic or actinic keratoses, skin tags, warts, and superficial basal cell or squamous cell carcinomas. Superficial shave biopsies should not be used for pigmented lesions; an unsuspected melanoma cannot be properly staged if partially removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/4,5,7,20\">",
"     4,5,7,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Pigmented lesions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Punch biopsies are performed with round, disposable knives ranging in diameter from 2 to 10 mm; 3 mm is the smallest size likely to give sufficient tissue for consistently accurate histologic diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/21\">",
"     21",
"    </a>",
"    ]. The punch is an ideal procedure for diagnostic skin biopsy or removing small lesions. It often provides a better cosmetic result than a shave biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/3,7,19\">",
"     3,7,19",
"    </a>",
"    ]. Punch biopsies are easily mastered by most practitioners, are quick, and have a low incidence of infection, bleeding, nonhealing, or significant scarring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/3,7,19\">",
"     3,7,19",
"    </a>",
"    ]. They can heal by secondary intention, but punches greater than 3 mm may produce unacceptable scarring and are best closed with one or two sutures.",
"   </p>",
"   <p>",
"    Excisions are performed for lesions that require complete removal for diagnostic or therapeutic purposes and for lesions that cannot be adequately biopsied with a punch due to size, depth, or location. An excisional biopsy allows for histopathologic examination of an entire lesion. Another advantage of an excisional biopsy is the amount of tissue that can be excised, allowing for multiple studies (culture, histopathology, immunofluorescence, electron microscopy) from one biopsy site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. Excisions are especially well suited for removal of large skin tumors or inflammatory disorders deep in the skin involving the panniculus.",
"   </p>",
"   <p>",
"    Excisions require the greatest amount of expertise and time; they almost always require sutures, and are more easily performed with an assistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. We recommend that practitioners receive clinical training before attempting an excisional biopsy, or refer patients requiring an excision to a qualified dermatologist or surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Shave biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shave biopsies can be either superficial or deep. Superficial shave biopsies are done across or nearly parallel to the skin surface and extend into the epidermis only or epidermis and limited superficial dermis (",
"    <a class=\"graphic graphic_figure graphicRef70126 \" href=\"mobipreview.htm?5/23/5493\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The shave biopsy can be facilitated by raising the lesion with a wheal of injected anesthetic, allowing the lesion to be propped up and stabilized between the thumb and forefinger (",
"    <a class=\"graphic graphic_figure graphicRef82624 \" href=\"mobipreview.htm?24/47/25331\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/6,10,19\">",
"     6,10,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When performing a superficial shave biopsy, a number 15 blade on a scalpel is held tangential to the skin surface. The lesion is then removed with a forward smooth sweeping stroke of the blade going just under and across the lesion (",
"    <a class=\"graphic graphic_figure graphicRef82624 \" href=\"mobipreview.htm?24/47/25331\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The slightly deeper shave biopsy allows for sampling of dermis and epidermis (",
"    <a class=\"graphic graphic_figure graphicRef70126 \" href=\"mobipreview.htm?5/23/5493\">",
"     figure 1",
"    </a>",
"    ), important for assessing basal cell and squamous cell carcinomas (superficial shave biopsies of exophytic tumors may only contain epidermal tissue, preventing histologic differentiation between in-situ and invasive malignancy). For this biopsy, the clinician holds the scalpel like a pencil, makes a small vertical incision into the skin with the beveled tip of the number 15 scalpel blade, then turns the scalpel and moves the blade forward in a horizontal sawing motion, turning the blade up towards the surface to finish the excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/9\">",
"     9",
"    </a>",
"    ]. The defect created is that of a saucer (hence the alternative name \"saucerization\" biopsy).",
"   </p>",
"   <p>",
"    In both biopsies, the index finger can be placed on top of the lesion near the end of the excision to stabilize and prevent tearing. Since the angle of the blade controls the depth of the biopsy, attention should be paid to the angle entering and exiting the skin.",
"   </p>",
"   <p>",
"    A double-edge razor blade cut longitudinally also can be used for shave biopsies (",
"    <a class=\"graphic graphic_picture graphicRef57311 \" href=\"mobipreview.htm?17/4/17487\">",
"     picture 2",
"    </a>",
"    ). The razor technique has several advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is sharper than most surgical blades",
"     </li>",
"     <li>",
"      The razor can be bent concave or convex with the thumb and forefinger to better conform to the surface being cut",
"     </li>",
"     <li>",
"      Depth is easily controlled by increasing or decreasing the convexity of the curve",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Devices are available that provide a holder or handle for the razor blade and many clinicians find these helpful.",
"   </p>",
"   <p>",
"    Curved scissors are an efficient means of removing skin tags and other small exophytic growths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/5\">",
"     5",
"    </a>",
"    ]. The lesion to be removed is stabilized with toothed forceps, then cut at the base.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hemostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding following small shave biopsies can often be controlled with pressure alone. Persistent oozing may be stopped with 10 to 20 percent aluminum chloride in absolute alcohol (eg, Drysol&reg;). Other hemostatic agents, in order of increasing corrosiveness, are Monsel's solution (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/18/19747?source=see_link\">",
"     ferric subsulfate",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7794?source=see_link\">",
"     trichloroacetic acid",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    . Monsel's solution is more effective than aluminum chloride, but also causes more tissue destruction and, like silver nitrate, can result in skin pigmentation (permanent tattoos) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/3,11,22\">",
"     3,11,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The wound must be as dry as possible for hemostatic agents to be effective. The agent is applied with a cotton applicator using firm pressure with a twisting motion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/11\">",
"     11",
"    </a>",
"    ]. Excellent hemostasis generally can be achieved in patients with bleeding disorders or in those taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    with the combined use of aluminum chloride and several minutes of direct pressure over the wound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Punch biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Punch biopsies are relatively simple and the specimen is a cone shaped core of tissue with its widest diameter at the skin surface and narrowest at the biopsy base. The direction of the skin tension lines at the biopsy site should be determined prior to performing a punch biopsy. Raise an intradermal welt (wheal) with the anesthetic and select the appropriate size punch. Stabilize the skin with the thumb and forefinger, stretching it slightly perpendicular to the normal skin tension lines; this will produce an oval rather than round wound, facilitating closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Place the punch perpendicular to the skin and apply firm and constant downward pressure with a circular twisting motion (",
"    <a class=\"graphic graphic_picture graphicRef65739 \" href=\"mobipreview.htm?24/6/24673\">",
"     picture 3",
"    </a>",
"    ). Avoid removing the punch to \"check the progress;\" this may result in a ragged wound and a shredded biopsy sample [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/11,19\">",
"     11,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A definite \"give\" occurs when the punch reaches the subcutaneous fat, indicating that a full-thickness cut has been made. Remove the punch and apply downward finger pressure at the sides of the wound to pop up the core. Completely elevate the core with gentle use of forceps or a needle tip and excise it at its base with small tissue scissors. Apply pressure to the wound with gauze in preparation for closure.",
"   </p>",
"   <p>",
"    Punch biopsies of the scalp for diagnosis of hair disorders are best accomplished using a 4 mm punch and holding it at 20&ordm; to the surface of the scalp, roughly along the axis of the hair follicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/7,23\">",
"     7,23",
"    </a>",
"    ]. Biopsies of scalp lesions suspected of being malignant are performed in the same manner as other punch biopsies, with the punch perpendicular to the skin surface. Scalp biopsies bleed profusely and usually require the presence of an assistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Punch biopsies can be closed with one or two sutures or allowed to heal by secondary intention. A randomized trial in volunteers found that the results with secondary intention healing after 4 mm punch biopsies were at least as good as with suturing, but that patients preferred the appearance of 8 mm punch biopsies that were sutured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wounds that are allowed to heal by secondary intention may be treated with a hemostatic agent such as aluminum chloride or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/4/18499?source=see_link\">",
"     absorbable gelatin",
"    </a>",
"    (Gelfoam&reg;); do not apply a hemostatic agent if sutures are to be used. Contraindications to suturing include biopsies in infected or poorly healing skin; these wounds heal better by secondary intention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The direction of the skin tension lines should be determined after performing a field block in preparation for an excision. Align the long axis of the excision parallel to the skin tension lines. Using a surgical marking pen, draw an ellipse around the lesion to be excised, including a 2 to 5 mm margin of normal skin around the lesion, with 30&ordm; angles at each apex, and the length three times the width [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Holding the scalpel with a number 15 blade like a pencil, begin the incision at one apex with the blade perpendicular to the skin. As the incision progresses, use more of the belly of the blade, raising it to the perpendicular again at the next apex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The blade should be angled away from the lesion, slightly undermining the wound edge. This will allow for easier eversion of the wound edge during closure, improving the cosmetic result and decreasing the risk of dehiscence. Avoid crosshatching the incisions at the apices and nicking the sample. It is not necessary to go through the entire thickness of dermis on the first stroke, although ultimately the incision must extend completely through the dermis and be deep enough to see subcutaneous fat when the sample is removed.",
"   </p>",
"   <p>",
"    Carefully lift the sample edge with fine forceps once the ellipse has been incised and completely undermine the sample at the level of the subcutaneous fat with scalpel or scissors. Do not remove more tissue at the center than at the apices. Apply pressure to the wound with gauze in preparation for closing.",
"   </p>",
"   <p>",
"    It may be technically easier to perform a diamond-shaped excision for small lesions and a hexagonal-shaped excision for larger lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/4\">",
"     4",
"    </a>",
"    ]. For diamond excisions, the blade is inserted vertically into the skin to make the four straight-line incisions of the diamond. For the hexagon, two straight, parallel lines are incised on either side the lesion and then connected at each end by two more straight incisions to form the hexagon.",
"   </p>",
"   <p>",
"    The edges of the wound may need to be undermined prior to closing excisional wounds, either sharply with a scalpel or bluntly with scissors. Blunt dissection is performed by advancing the closed scissors under the wound edge at the dermal-subcutaneous junction, and quickly spreading them open. The width of undermining varies with the size of the wound; for most wounds 5 to 10 mm is sufficient. Undermining allows the skin edges to evert more easily and reduces tension on the sutures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/3,6,7,11,18\">",
"     3,6,7,11,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pigmented lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of malignant melanoma must always be considered when removing pigmented lesions. The preferred biopsy technique for all pigmented lesions and lesions suspicious for or suggestive of melanoma is the excisional biopsy. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Excision'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Small lesions (less than 4 mm in diameter) can be biopsied using punch technique, provided that the entire lesion is removed with the punch. Larger lesions should be biopsied by elliptical excision whenever possible. When not possible or practical, a deep shave that extends well down into the reticular dermis may be performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/25\">",
"     25",
"    </a>",
"    ]. Ideally, the initial specimen should be removed to the level of subcutaneous fat to allow for proper staging if it is a melanoma. Such a shave procedure should generally only be performed by a clinician with experience in the technique; referral to an experienced dermatologist or surgeon is preferred.",
"   </p>",
"   <p>",
"    Partial punch biopsies of lesions suspicious for melanoma generally are not recommended. Partial punch biopsies have a higher potential for misdiagnosis than other techniques and are less likely to provide accurate information for histologic staging of melanoma, which is important for management and prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/20,26\">",
"     20,26",
"    </a>",
"    ]. Due to the possibility of sampling errors, close follow-up is warranted for lesions that are determined to be benign after a partial biopsy.",
"   </p>",
"   <p>",
"    Thus, lesions that appear too large for ease of biopsy by a primary clinician should be referred to a dermatologist or surgeon. &nbsp;It is preferable to have the entire lesion removed at time of biopsy, for both diagnostic and therapeutic purposes. Pigmented lesions should never be destroyed by cryosurgery or cautery and all biopsy specimens should be submitted for histopathologic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Processing the biopsy sample",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specimen should be placed in a 10 percent buffered formalin solution for evaluation by light microscopy; each specimen is placed into a separate bottle and identified. Special studies require special handling (",
"    <a class=\"graphic graphic_table graphicRef68516 \" href=\"mobipreview.htm?8/30/8683\">",
"     table 3",
"    </a>",
"    ). Specimens less than 1 cm in greatest dimension can be adequately fixed in 30 mL of formalin; larger specimens require more formalin and should be sectioned to ensure adequate fixation. The pathologist should be informed if the specimen is sectioned and advised of the orientation of the lesion by sectioning through its center and marking the normal skin borders with a surgical marker.",
"   </p>",
"   <p>",
"    Since many dermatologic diagnoses are predicated upon clinicopathological correlation, the specimen request form should include adequate information regarding the lesion or process biopsied; in addition to the lesion site, size, and appearance, a brief history often helps achieve a more precise diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Suturing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary closure of a punch wound can be accomplished with one or two, single-layer, interrupted sutures. Some punch wounds can be allowed to heal by secondary intention (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Punch biopsy'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Excisions can be closed in one or two layers; two-layer closures yield better cosmetic results for larger wounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Choice of suture and needle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The qualities most important in suture are flexibility, strength, secure knotting, and infection potential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/27\">",
"     27",
"    </a>",
"    ]. The two major categories of suture are absorbable and nonabsorbable. Absorbable suture is made from synthetic polymer or mammalian-derived collagen (gut). Common synthetic absorbables include polyglactic acid (Vicryl), polyglycolic acid (Dexon), and polydixanone (PDS). Absorbable sutures are usually placed deep in larger wounds to reduce skin tension for the final closure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=see_link\">",
"     \"Closure of skin wounds with sutures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonabsorbable sutures are used for skin closure and permanent internal placement, such as cardiac valves. Common nonabsorbable sutures include silk, nylon (Ethilon), and polypropylene (Prolene). Silk and nylon sutures can be braided, adding strength and improving knotting potential, but they are more likely to harbor infection. Polypropylene and unbraided nylon are monofilaments and are less likely to harbor infection, but knots are less secure and more difficult to tie [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/10,27\">",
"     10,27",
"    </a>",
"    ]. Polypropylene should be considered for the scalp, primarily because it is blue and easy to see. Silk and gut, as natural materials, cause considerable tissue inflammation and have been largely replaced by synthetic suture material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/10,27\">",
"     10,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suture size is indicated by the code O: the more O's, the smaller the suture diameter. Generally, 4-O or 5-O monofilament nylon can be used on the body and scalp, and 6-O nylon on the face [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/6,11\">",
"     6,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suture needles are made of noncorrosive stainless steel that is forged to achieve maximum strength and ductility, the ability to bend under pressure without breaking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/27\">",
"     27",
"    </a>",
"    ]. Three types of needle points are common: cutting; tapered; and blunt. Cutting needles allow for easy passage through tough tissue and are ideal for skin.",
"   </p>",
"   <p>",
"    A code has been developed to denote the purpose of the needle. For skin (FS) and cutting needles (CE) are used on thick skin, while plastic (P), plastic skin (PS), and premium (PRE) are used for cosmetic closures. The size of the needle is ranked by a number, with higher numbers identifying larger needles. Needle curvature is measured in terms of proportion of a circle, with one-quarter, one-half, and three-eighths curves available.",
"   </p>",
"   <p>",
"    Most biopsy wounds in thick skin can be closed using an FS-3 or CE-3 needle; P-3 can be used for the face, all with a three-eighths curvature. C-17 needles were developed specifically to close punch biopsies and are less expensive than FS, CE, P, or PRE needles.",
"   </p>",
"   <p>",
"    Reassess the appropriateness of the instruments when wound closing seems more difficult than expected. Needle selection is often a prime factor determining the ease of suturing and final cosmetic result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/18\">",
"     18",
"    </a>",
"    ]. A larger needle may decrease the difficulty of the job.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Closing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common closure technique is a simple, interrupted suture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To begin, grasp the needle with the needle-holder at midpoint or about one-third the distance from the eye. This will provide maximum driving force and diminish the likelihood of bending or breaking the needle. A palm grip is recommended to increase the driving force of the needle through the skin. Place the handle of the holder in the palm, wrap the thumb and fingers around the handles, and extend the index finger down over the tip of the holder near the needle.",
"     </li>",
"     <li>",
"      The needle point is placed perpendicular to the skin surface about 2 mm away from the wound edge and is driven down, then up into the center of the wound. A second insertion begins in the center of the wound and exits the skin on the opposite side, 2 mm from the wound edge, perpendicular to the surface. If done properly, the suture will make a flask-shaped loop; the loop beneath the skin surface is farther apart than the entry and exit points on the surface. A needle exit in the middle of the wound is not necessary for small excisional wounds and for most punch wounds, but depends upon the size of the needle and the ease that the wound edges can be approximated and everted.",
"     </li>",
"     <li>",
"      To tie the suture, hold the needle holder parallel to the long axis of the wound with the free end and needle end of the suture on either side of the holder. Wrap the needle end of the suture twice around the holder, then grasp the free end of the suture with the holder and pull through, tightening the knot. At this point the needle end and free end of the suture should have switched sides relative to the beginning. The process is repeated as needed, reversing the position of the free end and needle end of the suture with each knot. \"Approximate, don't strangulate\" acknowledges the importance of proper tension on the suture. Excessive tension can be recognized by blanching of the wound edges, and may indicate the need for subcutaneous sutures or simply less tension on each suture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Placement of sutures for elliptical excisions can be facilitated by following the \"rule of halves\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/11\">",
"     11",
"    </a>",
"    ]. The wound is divided in half by the initial suture placement, and each half is itself halved by the subsequent placement of sutures. Similar halving continues until all wound edges are approximated. Starting the initial suture at an apex rather than the middle runs the risk of \"dog ears\" at the opposite apex owing to the creation of uneven wound edges.",
"   </p>",
"   <p>",
"    The skin tension can be reduced in large wounds by placing a temporary initial suture at the midpoint of the wound, but farther from the edge than usual. At a later time, this suture can be removed as the wound is approximated with the permanent sutures.",
"   </p>",
"   <p>",
"    Diamond and hexagonal excisions are easily closed by placing the initial sutures at the two opposing points of the diamond or four opposing points of the hexagon, then adding other sutures as necessary to completely approximate the wound. The straight lines of the diamond and hexagon provide better approximation of edges for the beginner than do the curved surfaces of the ellipse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Wound dressing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wounds heal faster when moist and under an occlusive or semiocclusive dressing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/22\">",
"     22",
"    </a>",
"    ]. Choices for topical occlusive ointments include plain petrolatum (or Aquaphor&reg;) and antibiotic ointments (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     Neomycin",
"    </a>",
"    containing agents should be avoided due to the relatively high incidence of contact allergy. Contact dermatitis can also occur with bacitracin, although this occurs less frequently than with neomycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial, similar rates of infection were found in patients who used white petrolatum for postoperative wound care following dermatologic procedures compared with those who applied",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, to avoid the potential complication of contact dermatitis, we suggest the use of petrolatum for dressing clean wounds from skin biopsies and excisions.",
"   </p>",
"   <p>",
"    All biopsy wounds should be dressed with a thin film of the occlusive ointment to prevent crust formation, then covered with an adhesive bandage or other nonadherent covering and topped with a gauze dressing and tape [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/11,22\">",
"     11,22",
"    </a>",
"    ]. The dressing should be removed in 12 to 24 hours and cleaned with soap and water twice daily. After cleaning, the wound should be covered with the occlusive ointment. Wounds healing by secondary intention need to be redressed after each cleaning until healed over or for at least 5 days; covering the wound site is optional for sutured wounds. Showering is permitted after 24 hours for sutured wounds, but bathing and use of hot tubs are prohibited until the sutures are removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Suture removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a balance between the tendency for wound dehiscence or stretching if the sutures are removed too early and the production of suture marks if they remain too long [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/10,27\">",
"     10,27",
"    </a>",
"    ]. Sutures on the face generally can be removed in 3 to 5 days, followed by the application of semipermeable adhesive strips to reduce wound tension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/11,22,27\">",
"     11,22,27",
"    </a>",
"    ]. Sutures on the chest, abdomen, arms, and scalp can be removed in 7 to 10 days, and those on the back and legs in 12 to 20 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/11,22,27\">",
"     11,22,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physicians should remove sutures from their patients to see the results of their suturing technique on wound healing. Crust should be washed away with wet gauze, then the suture gently lifted near the knot and one side cut close to the skin surface. The suture is removed by pulling across the wound surface; pulling away from the wound puts tension on the wound and may cause dehiscence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major complications of skin biopsy include bleeding, infection, and allergic reactions. Most bleeding can be controlled with simple pressure on the wound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/4\">",
"     4",
"    </a>",
"    ]. If this is not successful after 5 minutes, a single suture may be sufficient. If bleeding remains uncontrolled, remove the suture, find and tie off the bleeding vessel, then resuture.",
"   </p>",
"   <p>",
"    Bleeding and hematoma formation can be minimized by using a pressure dressing directly over the wound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/22\">",
"     22",
"    </a>",
"    ]. Tape a folded 4 x 4 gauze pad tightly over the wound or secure it with an elastic bandage or self-adhering wrap. An ice pack applied for 3 to 5 minutes several times during the first 24 hours will also help decrease bleeding, hematoma formation, pain, and edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection, though relatively uncommon, is usually the result of Staphylococcus, Streptococcus, or Candida [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/31\">",
"     31",
"    </a>",
"    ]. If the wound is frankly purulent or has an associated cellulitis, culture the discharge and begin oral antibiotics. Infected wounds in the hands, feet, and intertriginous areas are often infected with Candida and can respond to topical antifungal ointments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may have allergic reactions to topical antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/32\">",
"     32",
"    </a>",
"    ]; the wound will be red, itchy, and may have vesicles. If this occurs, stop the antibiotic and apply a topical corticosteroid ointment. Tape reactions are usually irritant rather than allergic and improve simply by not taping, or sometimes by changing the direction of the tape on the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40264/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DOCUMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All procedures must be documented in the medical record. Minimal content includes the location and nature of the lesion; indications for the procedure; what was done and how it was performed; specimen disposition; and instructions to and follow-up plans for the patient. The following are examples of patient instructions and procedure notes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sample patient instructions for wound care",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Open wounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biopsy done today will heal from the bottom up and sides inward. Remove the Band-Aid in 12 to 24 hours and clean it twice per day with soap and water. Apply a thin coat of antibiotic ointment such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    or Polysporin, unless otherwise instructed, then cover with a Band-Aid. This type of wound heals faster when covered. If you have a lot of itching, redness, drainage of pus, swelling, or pain, call the office. Tylenol or ice packs may be used for pain control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Sutured wounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biopsy done today has stitches that will need to be removed in _ days. Beginning tomorrow, remove the dressing, wash twice daily with soap and water, and then apply a thin film of antibiotic ointment such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"     Bacitracin",
"    </a>",
"    or Polysporin. Band-Aids are optional. Call the office if you experience significant redness, pain, itching, swelling, or drainage of pus. If you are unable to keep your appointment for suture removal, call the office. Tylenol or ice packs can be used for pain control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Sample procedure notes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Shave biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible diagnosis of basal cell carcinoma and need for biopsy confirmation was discussed with the patient, and consent for a shave biopsy of the left ear was obtained. The skin was prepped with alcohol; local anesthesia was obtained with 1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with epinephrine and NaHCO3. A shave biopsy into the dermis was performed with a razor, and hemostasis was achieved with AlCl3. The biopsy specimens were submitted to pathology in formalin. A Band-Aid dressing was applied. Wound instructions were given. The patient will return in two weeks for a wound check and review of pathology results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Punch biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible diagnosis of lupus was discussed with the patient and the need for two biopsies reviewed. Consent for the procedure was obtained. The skin of the right upper, inner, and outer arm was prepped with Hibistat and alcohol, and local anesthesia was obtained with 1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with epinephrine and NaHCO3. Punches of 3 mm were obtained from the outer and inner right arm to the depth of the subcutaneous fat, and each was closed with a 4-O nylon suture. The specimen from the outer arm was placed in formalin and from the inner arm into Michel's solution and submitted to pathology. Band-Aid dressings were applied. Wound care instructions were given. The patient will return in 10 days for suture removal and review of pathology results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Elliptical excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Description: atypical nevus 8 x 4 cm left upper back. The possible diagnosis, procedure, need for biopsy, potential complications, side effects, and scarring were discussed with the patient and consent for the procedure was obtained. The patient was placed in the prone position, local anesthesia was achieved using 1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with epinephrine and NaHCO3, and the skin was prepped with povidone-iodine [Betadine] and alcohol and draped in the usual sterile fashion. The lesion and a 2-mm clear margin was excised in an ellipse to the depth of the subcutaneous tissue. Wound edges were undermined bluntly, three 4-O Vicryl inverted mattress sutures were placed in the dermis. The wound was closed with five 4-O nylon sutures. A pressure dressing was applied. Wound care instructions were given. The specimen was sent to pathology in formalin. Final specimen length 2.5 cm. The patient tolerated the procedure well. She will return in 14 days for suture removal and review of pathology results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The skin biopsy is a simple procedure that can assist with the diagnosis of cutaneous disorders. Skin biopsies may be performed with shave, punch, or excisional techniques. The type of skin lesion and the location of the biopsy are important factors to consider when choosing which procedure to perform. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Site selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Choice of procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common anesthetic used for skin biopsies is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      . Epinephrine may be added to lidocaine to induce vasoconstriction, which decreases bleeding and prolongs anesthesia. Several techniques are useful for decreasing the pain associated with injection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Shave biopsies are typically used for lesions for which sampling of the full thickness of the dermis is not necessary. Shave biopsies are performed with a number 15 scalpel blade or a razor blade. Aluminum chloride or another topical hemostatic agent is used to control bleeding. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Choice of procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Shave biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Punch biopsies involve the removal of a core-shape piece of tissue and allow sampling of the deep dermis. Punch biopsy wounds can be closed with suture or left to heal by secondary intention. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Choice of procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Punch biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Excisions are more time consuming than punch or shave biopsies, but are useful for biopsies of larger or deeper lesions. Careful technique is necessary to achieve a good cosmetic result and to reduce the risk of complications (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Choice of procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Excision'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Excisional biopsy is the preferred procedure for biopsy of pigmented lesions that are suspicious for melanoma. Only clinicians who are experienced with the deep shave biopsy technique should perform this procedure on pigmented lesions. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pigmented lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical information is useful for pathologists as they interpret the findings in skin biopsies. A clinical description of the lesion and brief history should be submitted with a biopsy specimen. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Processing the biopsy sample'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wound care for a skin biopsy site should involve the application of an occlusive ointment. Potential complications of skin biopsy include bleeding and infection. Allergic reactions to topical antibiotics may also occur. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Wound dressing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Alguire, PC, Mathes, BM. Skin biopsy techniques for the internist. J Gen Intern Med 1998; 13:46. Reprinted in part with permission of Blackwell Science, Inc.",
"    </li>",
"    <li>",
"     Fitzpatrick, TB, Bernhard, JD. The structure of skin lesions and fundamental of diagnosis. In: Fitzpatrick, TB, Eisen, AZ, Wolff, K, et al (Eds), Dermatology in General Medicine, 3rd ed., McGraw-Hill, New York 1987. p. 47.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/3\">",
"      Pariser, RJ. Skin biopsy: Lesion selection and optimal technique. Mod Med 1989; 57:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/4\">",
"      Pinkus H. Skin biopsy: a field of interaction between clinician and pathologist. Cutis 1977; 20:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/5\">",
"      Arca MJ, Biermann JS, Johnson TM, Chang AE. Biopsy techniques for skin, soft-tissue, and bone neoplasms. Surg Oncol Clin N Am 1995; 4:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/6\">",
"      Bart RS, Kopf AW. Techniques of biopsy of cutaneous neoplasms. J Dermatol Surg Oncol 1979; 5:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/7\">",
"      Peters, MS, Winkelman, RK. The biopsy. Dermatol Clin 1984; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/8\">",
"      Krull EA, Babel DE. Diagnostic procedures of the skin. Part two: Skin biopsy and other tests. J Fam Pract 1976; 3:427.",
"     </a>",
"    </li>",
"    <li>",
"     Olbricht, S. Biopsy Techniques and Basic Excisions. In: Dermatology, 1st edition, Bolognia, JL, Rapini, RP, et al (Eds), Mosby, London 2003. p.2269.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/10\">",
"      Harrison PV. A guide to skin biopsies and excisions. Clin Exp Dermatol 1980; 5:235.",
"     </a>",
"    </li>",
"    <li>",
"     Dinehart, SM, Hanke, CW, Geronemus, RG. Dermatologic Surgery for Medical Students. Association of Academic Dermatologic Surgeons, Schaumburg 1993.",
"    </li>",
"    <li>",
"     Snell, G. Skin biopsy. In: Pfenninger, JL, Fowler, GC (Eds), Procedures for Primary Care Physicians. Mosby-Year Book, St. Louis 1994. p. 20.",
"    </li>",
"    <li>",
"     Ritchie, JM, Greene, NM. Local anesthetics. In: Gilman, AG, Rall, TW, Nics, AS, Taylor, P (Eds), The Pharmacological Basis of Therapeutics, 8th ed. Pergamon Press, New York 1990. p. 311.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/14\">",
"      Firoz B, Davis N, Goldberg LH. Local anesthesia using buffered 0.5% lidocaine with 1:200,000 epinephrine for tumors of the digits treated with Mohs micrographic surgery. J Am Acad Dermatol 2009; 61:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/15\">",
"      Krunic AL, Wang LC, Soltani K, et al. Digital anesthesia with epinephrine: an old myth revisited. J Am Acad Dermatol 2004; 51:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/16\">",
"      H&auml;fner HM, R&ouml;cken M, Breuninger H. Epinephrine-supplemented local anesthetics for ear and nose surgery: clinical use without complications in more than 10,000 surgical procedures. J Dtsch Dermatol Ges 2005; 3:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/17\">",
"      Chowdhry S, Seidenstricker L, Cooney DS, et al. Do not use epinephrine in digital blocks: myth or truth? Part II. A retrospective review of 1111 cases. Plast Reconstr Surg 2010; 126:2031.",
"     </a>",
"    </li>",
"    <li>",
"     Epperson, WJ. Laceration and incision repair. In: Pfenninger, JL, Fowler, GC (Eds), Procedures for Primary Care Physicians. Mosby-Year Book, St. Louis 1994. p. 7.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/19\">",
"      Grekin, RC. Simple dermatological surgical procedures. Res Staff Phys 1989; 35:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/20\">",
"      Ng JC, Swain S, Dowling JP, et al. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service. Arch Dermatol 2010; 146:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/21\">",
"      Todd P, Garioch JJ, Humphreys S, et al. Evaluation of the 2-mm punch biopsy in dermatological diagnosis. Clin Exp Dermatol 1996; 21:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/22\">",
"      Telfer NR, Moy RL. Wound care after office procedures. J Dermatol Surg Oncol 1993; 19:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/23\">",
"      Stengel FM. Indications and technique of biopsy for diseases of the scalp. J Dermatol Surg Oncol 1978; 4:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/24\">",
"      Christenson LJ, Phillips PK, Weaver AL, Otley CC. Primary closure vs second-intention treatment of skin punch biopsy sites: a randomized trial. Arch Dermatol 2005; 141:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/25\">",
"      Gambichler T, Senger E, Rapp S, et al. Deep shave excision of macular melanocytic nevi with the razor blade biopsy technique. Dermatol Surg 2000; 26:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/26\">",
"      Karimipour DJ, Schwartz JL, Wang TS, et al. Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma. J Am Acad Dermatol 2005; 52:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/27\">",
"      Moy RL, Waldman B, Hein DW. A review of sutures and suturing techniques. J Dermatol Surg Oncol 1992; 18:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/28\">",
"      Sheth VM, Weitzul S. Postoperative topical antimicrobial use. Dermatitis 2008; 19:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/29\">",
"      Smack DP, Harrington AC, Dunn C, et al. Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. JAMA 1996; 276:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/30\">",
"      Noe JM, Keller M. Can stitches get wet? Plast Reconstr Surg 1988; 81:82.",
"     </a>",
"    </li>",
"    <li>",
"     Bennett, RG. Microbiological considerations in cutaneous surgery. In: Bennett, RG (Ed), Fundamentals of Cutaneous Surgery. CV Mosby Company, St. Louis 1988. p. 136.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/32\">",
"      Gette MT, Marks JG Jr, Maloney ME. Frequency of postoperative allergic contact dermatitis to topical antibiotics. Arch Dermatol 1992; 128:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40264/abstract/33\">",
"      Grolnik, M. Factors involved in the production of adhesive plaster irritation. Am J Surg 1940; 50:63.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5577 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40264=[""].join("\n");
var outline_f39_20_40264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SITE SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BIOPSY TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Preparing the site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Choice of procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Shave biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hemostasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Punch biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pigmented lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Processing the biopsy sample",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Suturing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Choice of suture and needle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Closing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Wound dressing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Suture removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DOCUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sample patient instructions for wound care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Open wounds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Sutured wounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Sample procedure notes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Shave biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Punch biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Elliptical excision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5577\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5577|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/23/5493\" title=\"figure 1\">",
"      Shave biopsy depth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/47/25331\" title=\"figure 2\">",
"      Shave biopsy technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5577|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/16/41217\" title=\"picture 1\">",
"      Skin biopsy incision technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/4/17487\" title=\"picture 2\">",
"      Shave biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/6/24673\" title=\"picture 3\">",
"      Punch biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5577|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/63/18428\" title=\"table 1\">",
"      Indications for skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/31/13820\" title=\"table 2\">",
"      Supplies for skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/30/8683\" title=\"table 3\">",
"      Special studies skin biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=related_link\">",
"      Closure of skin wounds with sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_20_40265="Clinical manifestations and diagnosis of herpes simplex virus type 1 infection";
var content_f39_20_40265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/20/40265/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/20/40265/contributors\">",
"     Robyn S Klein, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/20/40265/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/20/40265/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/20/40265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/20/40265/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/20/40265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus type 1 (HSV-1), also known as herpes labialis, is the etiologic agent of vesicular lesions of the oral mucosa commonly referred to as \"cold sores.\" HSV-1 can also cause clinical disease in a wide variety of other anatomic locations including the genitalia, liver, lung, eye, and central nervous system. These infections can be severe, particularly in the setting of immunosuppression.",
"   </p>",
"   <p>",
"    The major clinical manifestations of HSV-1 infection and the methods used to establish the diagnosis will be reviewed here. The manifestations depend upon the anatomic site involved and whether the clinical episode is due to primary infection or reactivation disease. The treatment of HSV-1 related disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and treatment of HSV-2 infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRIMARY INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inoculation of HSV-1 at mucosal surfaces or skin sites permits entry of the virus into the epidermis, the dermis, and eventually to sensory and autonomic nerve endings. The onset of clinical illness is usually sudden, with the appearance of multiple characteristic vesicular lesions superimposed upon an inflammatory, erythematous base. Primary infection may also be associated with systemic symptoms, such as fever and malaise. In general, the severity of symptoms and the number of lesions is considerably less with reactivation. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Recurrent infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The lesions can be painful and last for 10 to 14 days. Vesicles are usually grouped in a single anatomic site; however, autoinoculation of distant locations can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/1\">",
"     1",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Other cutaneous manifestations'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Although the symptoms can be severe, most primary HSV-1 infections are asymptomatic. Retrospective studies demonstrate that only 20 to 25 percent of patients with HSV-1 antibodies and 10 to 20 percent of those with HSV-2 antibodies have a history of oral-labial or genital infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Viral shedding can lead to unsuspected transmission to others via contact with secretions or mucous membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RECURRENT INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once HSV infection has occurred, the virus lives in a latent state in nerve cell bodies in ganglion neurons and can reactivate. The frequency and severity of reactivation is determined by many factors, including immunodeficiency or stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to primary HSV-1, recurrent HSV-1 is rarely associated with systemic signs or symptoms except for local lymphadenopathy. The majority of patients are aware of prodromal symptoms that herald the onset of a reactivation episode, such as pain, burning, tingling, and pruritus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/6\">",
"     6",
"    </a>",
"    ]. These symptoms may last from 6 to 53 hours prior to the appearance of the first vesicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence patterns can demonstrate great variability from person to person. However, the specific triggers can be quite predictable for each individual patient and lesions tend to recur at the same site.",
"   </p>",
"   <p>",
"    Subclinical shedding is common in both immunocompetent and immunocompromised patients and is probably a key factor in transmitting virus to others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immunocompetent hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent episodes are usually of shorter duration than the primary episode. The median time from onset of prodromal symptoms to healing of the lesion is approximately five days.",
"   </p>",
"   <p>",
"    The frequency of reactivation is also influenced by the interaction between the viral subtype and the anatomic area where infection has occurred. HSV-1 has a specific tropism for oral mucosa while HSV-2 preferentially infects genital mucosa. In patients who have simultaneously acquired HSV-1 infection of both oral and genital mucosa, oral lesions recur much more frequently than genital lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In contrast, patients who have acquired HSV-2 infection of these same two sites have more genital recurrences than oral reactivation episodes.",
"   </p>",
"   <p>",
"    Recurrences may also demonstrate individual predictability in terms of precipitating factors, site of recurrence, and numbers of recurrences over time.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precipitating factors for HSV-1 recurrence include exposure to sunlight, fever, menstruation, and emotional stress [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/6\">",
"       6",
"      </a>",
"      ]. Trauma to the area of primary infection, such as trigeminal nerve manipulation (in the case of oral infection) or dental extractions can also trigger a recurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recurrences usually occur at the site of the primary infection and in adjacent areas, due to either centrifugal spread via peripheral nerves or contiguous spread to new epithelial cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/6,10\">",
"       6,10",
"      </a>",
"      ]. Occurrence at distant sites may be the result of new primary infection, autoinoculation, or rarely disseminated infection.",
"     </li>",
"     <li>",
"      Recurrences occur as frequently as once per month (24 percent) or as infrequently as twice per year (19 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/6\">",
"       6",
"      </a>",
"      ]. Some individuals have a primary attack without subsequent clinically recognized recurrences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial containment of HSV infection requires intact cellular immunity. Thus, immunocompromised hosts are at risk for increased frequency and severity of recurrent HSV infections. They are also at risk for dissemination of infection, which may include sites that are rarely involved in immunocompetent hosts, such as the lungs or gastrointestinal tract. Visceral dissemination is associated with high mortality. Risk factors for increased severity of HSV infection include history of HIV infection, malignancy, organ transplantation, malnutrition, pregnancy, and advanced age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/11-18\">",
"     11-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced HIV infection (CD4 count &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    are at increased risk for recurrent and extensive HSV infections. HSV infections can occur anywhere on the skin, often presenting as extensive oral or perianal ulcers. HIV-infected patients can also develop esophagitis, colitis, chorioretinitis, acute retinal necrosis, tracheobronchitis, and pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV infection also has ramifications for HIV disease. The presence of genital HSV lesions may increase the risk of acquiring HIV through sexual transmission. HSV can also affect the viral replication of HIV. Frequent mucosal reactivation of HSV is associated with higher levels of plasma HIV RNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/19\">",
"     19",
"    </a>",
"    ], while suppressive therapy for HSV is associated with measurable declines in HIV viremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant recipients who have been previously infected with HSV-1 have reactivation rates of 60 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/11\">",
"     11",
"    </a>",
"    ]. Most will excrete virus in throat washings during the first few weeks after grafting. These infections may be asymptomatic or may lead to tracheobronchitis, esophagitis, pneumonia, or hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Burns and other skin disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have disrupted skin integrity secondary to severe burns or primary dermatologic disorders, such as eczema and pemphigus vulgaris, are also at risk for severe HSV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/20\">",
"     20",
"    </a>",
"    ]. Eczema herpeticum, also called Kaposi's varicelliform eruption, is characterized by disseminated vesiculopustules and erosions due to HSV infection superimposed upon pre-existing dermatoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV-1 should be suspected at the site of burn wounds if the lesions continue to appear discolored and ulcerated. Reactivation of HSV-1 infection can also lead to dissemination to the respiratory tract or visceral organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/15,23\">",
"     15,23",
"    </a>",
"    ]. Necrotizing tracheobronchitis following intubation in burn patients has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ORAL INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gingivostomatitis and pharyngitis are the most frequent clinical manifestations of first-episode HSV-1 infection, whereas herpes labialis is the most frequent sign of reactivation disease. The most common clinical manifestations of HSV-1 occur in the oropharynx of children and adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary HSV-1 oral infection usually presents as gingivostomatitis in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. After a brief incubation period (median 6 to 8 days, range 1 to 26 days), fever, pharyngitis and painful vesicular lesions develop suddenly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/6\">",
"     6",
"    </a>",
"    ]. Lesions can occur anywhere on the pharyngeal and oral mucosa and progress over several days, eventually involving the soft palate, buccal mucosa, tongue, and the floor of the mouth. Gingivitis and extensions to lips and cheeks can be seen, with consequent difficulties in eating, drinking, and swallowing. Children may require hospitalization for pain control",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dehydration.",
"   </p>",
"   <p>",
"    Common systemic symptoms and signs include fever, malaise, myalgias, irritability, and cervical lymphadenopathy, which can last up to two weeks. Viral transmission can occur through close contact with oral lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary oral HSV-1 infection in adults can present as severe pharyngitis. In one study of 613 college students, clinical pharyngitis was due to HSV-1 in 5.7 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/26\">",
"     26",
"    </a>",
"    ]. The major presenting signs were pharyngeal edema (71 percent), tonsillar exudate (40 percent), and oral exudative and ulcerative lesions (34 percent). Other associated symptoms and signs can include fever, malaise, myalgia and cervical lymphadenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe mouth pain and fever usually persist for two to eight days, during which time vesicles crust over and heal; in comparison, cervical lymphadenopathy may persist for weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrences involving the oral cavity and lips are common; most patients (&gt;85 percent) develop prodromal symptoms about 24 hours before the appearance of painful lesions at the lip borders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. While most lesions are small (&lt;100 mm3), larger lesions can take longer to heal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/6\">",
"     6",
"    </a>",
"    ]. Lesions progress from vesicle to crust in about eight days, with significant diminution of pain after the first 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/6\">",
"     6",
"    </a>",
"    ]. Recurrences are not associated with systemic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In immunocompromised patients, HSV infection can lead to chronic mucocutaneous herpes simplex infection that may extend into deeper cutaneous layers, leading to easy friability and tissue necrosis. This can be associated with severe pain and atypical appearing lesions on examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/27\">",
"     27",
"    </a>",
"    ]. Mucocutaneous dissemination of HSV-1 should also raise suspicion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Burn injury patients may develop eczema herpeticum (also known as Kaposi's varicelliform eruption) characterized by severe oral-facial HSV. Vesicles and pustules can lead to extensive erosions that complicate recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent aphthous ulcers, which are most often confused with HSV infection, are never preceded by vesicles and occur exclusively on nonkeratinized mucosal surfaces such as the inner surfaces of lips, buccal mucosa, ventral tongue, and mucobuccal fold in the anterior part of the oral cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In contrast, recurrent oral HSV-1 lesions (\"cold sores\") occur at the border of the vermillion (ie, the colored portion of the lips). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25786?source=see_link&amp;anchor=H16#H16\">",
"     \"Oral lesions\", section on 'Aphthous ulcerations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other diseases that present with oral lesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe pharyngitis include aphthous stomatitis, syphilis, bacterial pharyngitis, enteroviruses (eg, herpangina), Epstein-Barr virus, and Stevens-Johnson syndrome. In the immunocompromised host, other considerations can include ulcerative lesions secondary to fungal infections, such as histoplasmosis. Available diagnostic techniques can be helpful in differentiating ulcers from HSV from other etiologies when the etiology is unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5738?source=see_link\">",
"     \"Evaluation of acute pharyngitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER CUTANEOUS MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-1 can cause primary infection anywhere on the skin, especially if there is disruption of skin integrity. Primary infections begin with a typical prodrome of pruritus and pain, followed by the development of vesicular lesions. Associated symptoms include neuralgia and lymphadenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also a variety of cutaneous manifestations associated with HSV-1 infection of the skin as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13886328\">",
"    <span class=\"h2\">",
"     Herpetic whitlow",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV infection of the finger, known as herpetic whitlow, can occur as a complication of primary oral or genital herpes by inoculation of the virus through a break in the skin barrier (",
"    <a class=\"graphic graphic_picture graphicRef52029 \" href=\"mobipreview.htm?9/30/9696\">",
"     picture 1",
"    </a>",
"    ). In one study, 80 percent of children with herpetic whitlows also had history of oral lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/32\">",
"     32",
"    </a>",
"    ]. Herpetic whitlow can be an occupational hazard (eg, in dentists and health care workers) that have been repeatedly exposed to infected secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/33\">",
"     33",
"    </a>",
"    ]. Untreated, these infections gradually heal over two to three weeks, but can recur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/32\">",
"     32",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Herpetic whitlow is often misdiagnosed as a bacterial infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/34\">",
"     34",
"    </a>",
"    ]. The distinction is important since antibiotics and drainage are not necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13886336\">",
"    <span class=\"h2\">",
"     Herpes gladiatorum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outbreaks of HSV-1 skin infections have also occurred among wrestlers and rugby players [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. This type of skin infection is referred to as \"herpes gladiatorum\". Lesions classically occur on the face, neck, and arms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13886374\">",
"    <span class=\"h2\">",
"     Erythema multiforme",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-1 infection may be associated with the onset of erythema multiforme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/37\">",
"     37",
"    </a>",
"    ]. This theory is supported by the detection of HSV genomic DNA in erythema multiforme lesions (",
"    <a class=\"graphic graphic_picture graphicRef80715 \" href=\"mobipreview.htm?15/18/15650\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31627071\">",
"    <span class=\"h2\">",
"     Eczema herpeticum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with atopic dermatitis are at risk for developing a skin complication called &ldquo;eczema herpeticum&rdquo; (also known as Kaposi&rsquo;s varicelliform eruption), particularly if they are taking immunosuppressive agents for control of their primary dermatologic condition.",
"   </p>",
"   <p>",
"    Eczema herpeticum is characterized by cutaneous pain and new skin lesions secondary to a viral infection (usually HSV-1), which can spread rapidly leading to severe morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/40\">",
"     40",
"    </a>",
"    ]. The rash of eczema herpeticum may sometimes be difficult to distinguish from the patient&rsquo;s baseline eczema if the latter is poorly controlled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may complain of new pustular lesions in association with fever. Such a presentation is also consistent with bacterial superinfection, which is one of the key considerations in the differential diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef62779 \" href=\"mobipreview.htm?22/57/23443\">",
"     picture 3",
"    </a>",
"    ). Prompt intravenous antiviral therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is indicated while awaiting diagnostic testing for HSV-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GENITAL HSV-1 INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of genital HSV infections are due to HSV-2. Genital HSV-1 infection is transmitted through oral-genital contact.",
"   </p>",
"   <p>",
"    Recurrences of genital HSV-1 infection are less common than when a patient acquires HSV-2 infection, since HSV-2 has specific tropism for genital epithelium. The acquisition of prior HSV-1 infection has an effect on the clinical manifestations of HSV-2 infection, since these patients are more likely to be asymptomatic.",
"   </p>",
"   <p>",
"    Transmission of HSV-1 to infants can occur at delivery, especially in the setting of primary infection of the mother. These topics are discussed in greater detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link\">",
"     \"Genital herpes simplex virus infection and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OCULAR INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary ocular HSV infections occur in less than 5 percent of patients, but can cause significant morbidity due to keratitis and acute retinal necrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent HSV-1 keratitis continues to be a leading cause of corneal blindness in industrialized nations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/43\">",
"     43",
"    </a>",
"    ]. HSV keratitis has an acute onset with symptoms of pain, visual blurring, and discharge. Physical examination is notable for chemosis, conjunctivitis, decreased corneal sensation, and characteristic dendritic lesions of the cornea (",
"    <a class=\"graphic graphic_picture graphicRef69359 \" href=\"mobipreview.htm?8/6/8289\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/44\">",
"     44",
"    </a>",
"    ]. The evaluation and management of herpes simplex virus keratitis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33992?source=see_link\">",
"     \"Herpes simplex keratitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute retinal necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute retinal necrosis (ARN) is a rare, potentially blinding retinal disease resulting from ocular infection with HSV or varicella-zoster virus (VZV). ARN is characterized by decreased vision and can occur in immunocompetent hosts, pregnant females, and in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Bilateral ARN has been reported in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=see_link\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study of 28 immunocompetent patients with ARN assessed the etiologic agent with use of PCR testing of vitreous and aqueous specimens with the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral etiologies included varicella-zoster (13 patients), HSV-1 (7 patients), HSV-2 (6 patients), and cytomegalovirus (1 patient).",
"     </li>",
"     <li>",
"      Six of seven patients with HSV-1 ARN had a history of HSV encephalitis.",
"     </li>",
"     <li>",
"      The median age of the HSV-1 infected patients was 47 years; the median age of the HSV-2 patients was 20 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other case reports have also confirmed an association between HSV-1 encephalitis and ARN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Conjunctivitis and blepharitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-1 can present as a unilateral conjunctivitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blepharitis with the development of vesicles on the lid margin. Associated symptoms include chemosis, edema of the eyelids, and tearing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chorioretinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorioretinitis, also known as posterior uveitis, is a manifestation of disseminated HSV infection that can be seen in neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/25,51\">",
"     25,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     NEUROLOGIC SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-1 causes sporadic cases of encephalitis with high rates of morbidity and mortality. The clinical syndrome is often characterized by the rapid onset of fever, headache, seizures, focal neurologic signs, and impaired consciousness. This topic is discussed in great detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=see_link\">",
"     \"Herpes simplex virus type 1 encephalitis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A variety of other neurologic syndromes have been linked to infection with HSV including aseptic meningitis, autonomic dysfunction, transverse myelitis, benign recurrent lymphocytic meningitis, and Bell's palsy. The strength of these various associations varies.",
"   </p>",
"   <p>",
"    Herpes simplex virus activation has become widely accepted as the likely cause of Bell's palsy in most cases. In one study, HSV-1 genomes were identified in facial nerve endoneurial fluid and auricular muscle in 11 of 14 patients undergoing decompression surgery for Bell's palsy but in none of the controls (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36216?source=see_link\">",
"     \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    HSV infection can be associated with aseptic meningitis, in the setting of primary genital HSV infection, and Mollaret's meningitis, a form of benign recurrent aseptic meningitis. Both clinical syndromes are more frequently related to HSV-2 rather than HSV-1 infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/3/15417?source=see_link&amp;anchor=H7#H7\">",
"     \"Aseptic meningitis in adults\", section on 'Recurrent (Mollaret's) meningitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various case reports have appeared in the literature regarding a link between HSV infection and transverse myelitis, although this association has not been well-established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autonomic dysfunction, with hyperesthesia or anesthesia of the perineal region with concomitant urinary retention can occur with primary genital HSV infection. Physical examination may be notable for increased bladder size on percussion, decreased sacral sensation and poor rectal tone (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Extragenital complications'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     HEPATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fulminant hepatitis is a rare complication of HSV infection. Both HSV-1 and HSV-2 have been implicated as etiologic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Those at risk include neonates, patients taking steroids, HIV-infected patients, those with cancer or myelodysplastic syndromes, and pregnant females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/11,53-55\">",
"     11,53-55",
"    </a>",
"    ]. HSV hepatitis has also been reported as an early cause of death after liver transplantation with concomitant lung and gastrointestinal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/11\">",
"     11",
"    </a>",
"    ]. HSV-related hepatitis has also been reported rarely in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV hepatitis presents as a fulminant disease that is usually fatal in untreated individuals (&gt;80 percent mortality) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/11,55\">",
"     11,55",
"    </a>",
"    ]. Clinical features include fever (82 percent), anorexia with nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting (18 percent), abdominal pain (33 percent), leukopenia (43 percent), and coagulopathy (20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/55\">",
"     55",
"    </a>",
"    ]. Typical oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genital lesions occur in 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/55\">",
"     55",
"    </a>",
"    ]. Some patients have evidence of disseminated extrahepatic involvement in lung, lymph nodes, spleen, or adrenal glands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the patient without any evidence of skin lesions, the approach to diagnosis of HSV hepatitis may include tissue sampling (liver biopsy) or detection of viremia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one case series of five patients, the diagnosis was established through transjugular liver biopsy, which demonstrated the presence of intranuclear inclusions and the presence of HSV antigens by immunofluorescence.",
"     </li>",
"     <li>",
"      In another retrospective case series of four patients who developed acute liver failure without evident skin lesions, the diagnosis of HSV was made through detection of high-level viremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    has sometimes been life-saving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/11,53\">",
"     11,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RESPIRATORY TRACT INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children may develop epiglottitis or laryngitis (herpetic croup) with nonproductive cough and stridor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/33\">",
"     33",
"    </a>",
"    ]. In most patients, the illness is self-limited, lasting 10 to 14 days without complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HSV-1 pneumonitis is uncommon, but can be seen in immunocompromised patients and may be due to direct extension from the upper airways secondary to tracheobronchitis. Cases have been reported in burn patients, solid organ and hematopoietic stem cell transplant recipients, patients with malignancy, pregnancy, and HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/18,23,57-59\">",
"     18,23,57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV detection from respiratory secretions has been reported in mechanically ventilated immunocompetent hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. It is often unclear as to whether HSV recovery from the respiratory tract reflects true bronchopneumonitis, viral contamination of the lower tract because of instrumentation from the oropharynx, or local tracheobronchial viral reactivation without parenchymal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     HSV ESOPHAGITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised hosts are at risk for HSV esophagitis, which usually presents with odynophagia, dysphagia, or retrosternal chest pain. HSV esophagitis may result from direct extension from the oropharynx or through reactivation and spread through the vagus nerve to the mucosa. This topic is discussed in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6647?source=see_link\">",
"     \"Herpes simplex virus infection of the esophagus\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HSV infection can be made by a variety of techniques including viral culture, serology, immunofluorescence or a bedside Tzanck prep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Viral culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HSV infection is generally based upon tissue culture identification. The alcohol-wiped vesicle should be gently \"unroofed\" with a sterile needle. The vesicular fluid can be removed with a sterile cotton swab and placed in viral culture medium.",
"   </p>",
"   <p>",
"    Vesicles contain the highest titers of virus within the first 24 to 48 hours of their appearance (89 percent positive) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/6\">",
"     6",
"    </a>",
"    ]. In general, however, recovery of virus from secretions is possible in only 7 to 25 percent of patients with active lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/6\">",
"     6",
"    </a>",
"    ]. Viral medium and slides should be immediately transported to the appropriate laboratory, but may be stored at 4&ordm;C for up to nine hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/6\">",
"     6",
"    </a>",
"    ]. The characteristic cytopathic effects appear in the selected cell line within 24 to 48 hours, especially if the initial inoculum is high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Immunofluorescence staining",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slides prepared from scrapings may be examined for herpes antigens via immunofluorescence microscopy. This technique has been made possible by the generation of HSV type-specific monoclonal antibodies that permit identification and typing of isolates in tissue samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/64\">",
"     64",
"    </a>",
"    ]. Slides containing cells from suspected HSV lesions or from neural ganglion tissue specimens should be fixed with ethanol or methanol and immediately transported to the appropriate laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various serological assays have been used for diagnosis of HSV infection. They include virus neutralization, complement fixation, passive hemagglutination, ELISA, complement-mediated cytolysis, antibody-dependent cellular lysis, and radioimmunoassays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Type specific antibodies to HSV develop during the first several weeks after primary infection and persist indefinitely. Serologic testing has limited applications as illustrated in the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary infection may be diagnosed in patients who are HSV antibody-negative but who have positive viral cultures and evidence of acute infection. In addition, a fourfold or greater rise in antibody titers is observed between acute and convalescent sera in patients with primary infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IgM antibodies may be useful in diagnosing neonatal infections, which appear during the first four weeks of infection and persist for months (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28041?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of TORCH infections\", section on 'Screening for TORCH infections'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Determining the HSV subtype may be helpful in certain circumstances due to its prognostic significance. Serologies may be considered in patients with a history of genital lesions who do not have any active lesions at the time of the patient encounter. In this situation, it may be useful to distinguish HSV-1 from HSV-2 infection when trying to predict risk of recurrence, which is lower in the setting of HSV-1 infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link&amp;anchor=H24#H24\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;While viral culture has remained the standard diagnostic method for isolating HSV, real-time HSV PCR assays have emerged as a more sensitive method to confirm HSV infection in clinical specimens obtained from genital ulcers and mucocutaneous sites. In patients with symptoms of encephalitis, the gold standard for establishing the diagnosis of HSV-1 infection is the detection of HSV DNA in cerebral spinal fluid specimens by PCR testing, which has high sensitivity and specificity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34789?source=see_link\">",
"     \"PCR testing for the diagnosis of herpes simplex virus in patients with encephalitis or meningitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of PCR is also utilized in the diagnosis of ocular infections, such as acute retinal necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/48,69\">",
"     48,69",
"    </a>",
"    ]. The use of quantitative PCR is being explored to determine if declines in HSV viral load are prognostic for improved visual acuity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Tzanck smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Tzanck smear, which exhibits the cytopathic effect of herpes viruses, can be performed in patients with active lesions. However, it has limited utility since it is only helpful if positive. Furthermore, only a viral culture will determine the presence of HSV-1, HSV-2, or other herpes viruses.",
"   </p>",
"   <p>",
"    Other disadvantages include the need for expert slide preparation and interpretation. Slides prepared from lesion scrapings are fixed with ethanol or methanol and stained with Giemsa or Wright stain preparations. The presence of multinucleated giant cells indicates infection with either HSV or varicella-zoster virus (VZV). Papanicolaou cervicovaginal stains also can demonstrate intranuclear inclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/20/40265/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/24/4482?source=see_link\">",
"       \"Patient information: Cold sores (oral herpes) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/3/36916?source=see_link\">",
"       \"Patient information: Genital herpes (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2029158\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herpes simplex virus type 1 (HSV-1) is the etiologic agent of herpes labialis, which is characterized as vesicular lesions of the oral mucosa. Patients commonly referred to herpes labialis as \"cold sores&rdquo;. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inoculation of HSV-1 at mucosal or skin sites leads to viral entry into the epidermis, the dermis, and eventually to sensory and autonomic nerve endings. During primary infection, symptomatic patients develop sudden onset of multiple painful vesicular lesions grouped in a single anatomic site. These lesions can last for up to 10 to 14 days with or without systemic symptoms of fever and malaise. However, most primary HSV-1 infections are asymptomatic. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Primary infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After primary infection, HSV lives in a latent state in ganglion neurons and can reactivate. The majority of patients are aware of prodromal symptoms that herald the onset of a reactivation episode, such as pain, burning, tingling, and pruritus. The frequency and severity of reactivation is determined by many factors, including stress or any underlying immunodeficiency, such as HIV infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Recurrent infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the immunocompetent host, recurrent episodes are usually of shorter duration than the primary episode. The median time from onset of prodromal symptoms to healing of the lesion is approximately five days. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Immunocompetent hosts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with the immunocompetent host, the frequency and severity of recurrent infections are greater in the immunocompromised host, who is also at risk for disseminated HSV-1 infection to uncommon sites, such as the lungs or gastrointestinal tract. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Immunocompromised hosts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary HSV-1 oral infection usually presents as gingivostomatitis in children. After a brief incubation period, fever, pharyngitis and painful vesicular lesions develop suddenly, leading to difficulties in eating, drinking, and swallowing. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Oral infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HSV-1 infection can cause primary cutaneous infection anywhere on the skin, especially if there is disruption of skin integrity. Herpetic whitlow is seen primarily among dentists and healthcare workers with frequent contact with infected secretions while eczema herpeticum is seen mainly in patients with atopic dermatitis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Other cutaneous manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary ocular HSV infections occur in less than 5 percent of patients, but can cause significant morbidity due to keratitis and acute retinal necrosis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Ocular infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HSV-1 also causes sporadic cases of encephalitis with high rates of morbidity and mortality. The clinical syndrome is often characterized by the rapid onset of fever, headache, seizures, focal neurologic signs, and impaired consciousness. A variety of other neurologic syndromes have been linked to infection with HSV including aseptic meningitis, autonomic dysfunction, transverse myelitis, benign recurrent lymphocytic meningitis, and Bell's palsy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Neurologic syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HSV-1 infection can be made by a variety of techniques including viral culture, serology, immunofluorescence or polymerase chain reaction (PCR) testing. While viral culture has remained the standard diagnostic method for isolating HSV-1, real-time HSV PCR assays are more sensitive, although more expensive to perform. In patients with neurologic syndromes, PCR is the test of choice for cerebral spinal fluid specimens. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/1\">",
"      Glogau R, Hanna L, Jawetz E. Herpetic whitlow as part of genital virus infection. J Infect Dis 1977; 136:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/2\">",
"      Johnson RE, Nahmias AJ, Magder LS, et al. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989; 321:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/3\">",
"      Oliver L, Wald A, Kim M, et al. Seroprevalence of herpes simplex virus infections in a family medicine clinic. Arch Fam Med 1995; 4:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/4\">",
"      Corey L, Spear PG. Infections with herpes simplex viruses (1). N Engl J Med 1986; 314:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/5\">",
"      Freeman ML, Sheridan BS, Bonneau RH, Hendricks RL. Psychological stress compromises CD8+ T cell control of latent herpes simplex virus type 1 infections. J Immunol 2007; 179:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/6\">",
"      Spruance SL, Overall JC Jr, Kern ER, et al. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med 1977; 297:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/7\">",
"      Lafferty WE, Coombs RW, Benedetti J, et al. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987; 316:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/8\">",
"      Engelberg R, Carrell D, Krantz E, et al. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003; 30:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/9\">",
"      Young SK, Rowe NH, Buchanan RA. A clinical study for the control of facial mucocutaneous herpes virus infections. I. Characterization of natural history in a professional school population. Oral Surg Oral Med Oral Pathol 1976; 41:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/10\">",
"      Steiner I, Kennedy PG. Herpes simplex virus latent infection in the nervous system. J Neurovirol 1995; 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/11\">",
"      Kusne S, Schwartz M, Breinig MK, et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991; 163:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/12\">",
"      Johnson JR, Egaas S, Gleaves CA, et al. Hepatitis due to herpes simplex virus in marrow-transplant recipients. Clin Infect Dis 1992; 14:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/13\">",
"      BECKER W, NAUDE WD, KIPPS A, McKENZIE D. Virus studies in disseminated herpes simplex infections: association with malnutrition in children. S Afr Med J 1963; 37:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/14\">",
"      Muller SA, Herrmann EC Jr, Winkelmann RK. Herpes simplex infections in hematologic malignancies. Am J Med 1972; 52:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/15\">",
"      Foley FD, Greenawald KA, Nash G, Pruitt BA Jr. Herpesvirus infection in burned patients. N Engl J Med 1970; 282:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/16\">",
"      Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981; 305:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/17\">",
"      Hillard P, Seeds J, Cefalo R. Disseminated herpes simplex in pregnancy: two cases and a review. Obstet Gynecol Surv 1982; 37:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/18\">",
"      Frederick DM, Bland D, Gollin Y. Fatal disseminated herpes simplex virus infection in a previously healthy pregnant woman. A case report. J Reprod Med 2002; 47:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/19\">",
"      Schacker T, Zeh J, Hu H, et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/20\">",
"      Keane JT, Malkinson FD, Bryant J, Levin S. Herpesvirus hominis hepatitis and disseminated intravascular coagulation. Occurrence in an adult with pemphigus vulgaris. Arch Intern Med 1976; 136:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/21\">",
"      Kramer SC, Thomas CJ, Tyler WB, Elston DM. Kaposi's varicelliform eruption: a case report and review of the literature. Cutis 2004; 73:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/22\">",
"      Bartralot R, Garc&iacute;a-Patos V, Rodr&iacute;guez-Cano L, Castells A. Kaposi's varicelliform eruption in a patient with healing second degree burns. Clin Exp Dermatol 1996; 21:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/23\">",
"      Byers RJ, Hasleton PS, Quigley A, et al. Pulmonary herpes simplex in burns patients. Eur Respir J 1996; 9:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/24\">",
"      McCarthy DW, Qualman SJ, Rudman DT, et al. Herpetic tracheitis and brachial plexus neuropathy in a child with burns. J Burn Care Rehabil 1999; 20:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/25\">",
"      Annunziato PW, Gershon A. Herpes simplex virus infections. Pediatr Rev 1996; 17:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/26\">",
"      McMillan JA, Weiner LB, Higgins AM, Lamparella VJ. Pharyngitis associated with herpes simplex virus in college students. Pediatr Infect Dis J 1993; 12:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/27\">",
"      Westheim AI, Tenser RB, Marks JG Jr. Acyclovir resistance in a patient with chronic mucocutaneous herpes simplex infection. J Am Acad Dermatol 1987; 17:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/28\">",
"      Hardy WD. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. Am J Med 1992; 92:30S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/29\">",
"      Rodu B, Mattingly G. Oral mucosal ulcers: diagnosis and management. J Am Dent Assoc 1992; 123:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/30\">",
"      Herbert AA, Berg JH. Oral mucous membrane diseases of childhood: I. Mucositis and xerostomia. II. Recurrent aphthous stomatitis. III. Herpetic stomatitis. Semin Dermatol 1992; 11:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/31\">",
"      Woo SB, Sonis ST. Recurrent aphthous ulcers: a review of diagnosis and treatment. J Am Dent Assoc 1996; 127:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/32\">",
"      Walker LG, Simmons BP, Lovallo JL. Pediatric herpetic hand infections. J Hand Surg Am 1990; 15:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/33\">",
"      Mancao MY, Sindel LJ, Richardson PH, Silver FM. Herpetic croup: two case reports and a review of the literature. Acta Paediatr 1996; 85:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/34\">",
"      Szinnai G, Schaad UB, Heininger U. Multiple herpetic whitlow lesions in a 4-year-old girl: case report and review of the literature. Eur J Pediatr 2001; 160:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/35\">",
"      Anderson BJ. The epidemiology and clinical analysis of several outbreaks of herpes gladiatorum. Med Sci Sports Exerc 2003; 35:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/36\">",
"      Turbeville SD, Cowan LD, Greenfield RA. Infectious disease outbreaks in competitive sports: a review of the literature. Am J Sports Med 2006; 34:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/37\">",
"      Patel NN, Patel DN. Erythema multiforme syndrome. Am J Med 2009; 122:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/38\">",
"      Ng PP, Sun YJ, Tan HH, Tan SH. Detection of herpes simplex virus genomic DNA in various subsets of Erythema multiforme by polymerase chain reaction. Dermatology 2003; 207:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/39\">",
"      Weston WL, Morelli JG. Herpes simplex virus-associated erythema multiforme in prepubertal children. Arch Pediatr Adolesc Med 1997; 151:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/40\">",
"      Mackool BT, Goverman J, Nazarian RM. Case records of the Massachusetts General Hospital. Case 14-2012. A 43-year-old woman with fever and a generalized rash. N Engl J Med 2012; 366:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/41\">",
"      Nikkels AF, Pi&egrave;rard GE. Treatment of mucocutaneous presentations of herpes simplex virus infections. Am J Clin Dermatol 2002; 3:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/42\">",
"      Wollenberg A, Wetzel S, Burgdorf WH, Haas J. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol 2003; 112:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/43\">",
"      Cook SD. Herpes simplex virus in the eye. Br J Ophthalmol 1992; 76:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/44\">",
"      Teng CC. Images in clinical medicine. Corneal dendritic ulcer from herpes simplex virus infection. N Engl J Med 2008; 359:e22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/45\">",
"      Benz MS, Glaser JS, Davis JL. Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. Am J Ophthalmol 2003; 135:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/46\">",
"      Chiquet C, Thuret G, Poitevin-Later F, et al. Herpes simplex virus acute retinal necrosis during pregnancy. Eur J Ophthalmol 2003; 13:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/47\">",
"      Chau Tran TH, Cassoux N, Bodaghi B, Lehoang P. Successful treatment with combination of systemic antiviral drugs and intravitreal ganciclovir injections in the management of severe necrotizing herpetic retinitis. Ocul Immunol Inflamm 2003; 11:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/48\">",
"      Ganatra JB, Chandler D, Santos C, et al. Viral causes of the acute retinal necrosis syndrome. Am J Ophthalmol 2000; 129:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/49\">",
"      Chong EM, Wilhelmus KR, Matoba AY, et al. Herpes simplex virus keratitis in children. Am J Ophthalmol 2004; 138:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/50\">",
"      Gaynor BD, Wade NK, Cunningham ET Jr. Herpes simplex virus type 1 associated acute retinal necrosis following encephalitis. Retina 2001; 21:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/51\">",
"      Mets MB. Eye manifestations of intrauterine infections. Ophthalmol Clin North Am 2001; 14:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/52\">",
"      Galanakis E, Bikouvarakis S, Mamoulakis D, et al. Transverse myelitis associated with herpes simplex virus infection. J Child Neurol 2001; 16:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/53\">",
"      Pinna AD, Rakela J, Demetris AJ, Fung JJ. Five cases of fulminant hepatitis due to herpes simplex virus in adults. Dig Dis Sci 2002; 47:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/54\">",
"      Goodman ZD, Ishak KG, Sesterhenn IA. Herpes simplex hepatitis in apparently immunocompetent adults. Am J Clin Pathol 1986; 85:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/55\">",
"      Kaufman B, Gandhi SA, Louie E, et al. Herpes simplex virus hepatitis: case report and review. Clin Infect Dis 1997; 24:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/56\">",
"      Levitsky J, Duddempudi AT, Lakeman FD, et al. Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure. Liver Transpl 2008; 14:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/57\">",
"      Taplitz RA, Jordan MC. Pneumonia caused by herpesviruses in recipients of hematopoietic cell transplants. Semin Respir Infect 2002; 17:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/58\">",
"      Baras L, Farber CM, Van Vooren JP, Parent D. Herpes simplex virus tracheitis in a patient with the acquired immunodeficiency syndrome. Eur Respir J 1994; 7:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/59\">",
"      Afessa B. Mycobacterial and nonbacterial pulmonary complications in hospitalized patients with human immunodeficiency virus infection: a prospective, cohort study. BMC Pulm Med 2001; 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/60\">",
"      Remy DP, Kuzmowych TV, Rohatgi PK, Ortega LG. Herpetic bronchitis with a broncho-oesophageal fistula. Thorax 1995; 50:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/61\">",
"      Sherry MK, Klainer AS, Wolff M, Gerhard H. Herpetic tracheobronchitis. Ann Intern Med 1988; 109:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/62\">",
"      Luyt CE, Combes A, Nieszkowska A, et al. Viral infections in the ICU. Curr Opin Crit Care 2008; 14:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/63\">",
"      Corey L. Laboratory diagnosis of herpes simplex virus infections. Principles guiding the development of rapid diagnostic tests. Diagn Microbiol Infect Dis 1986; 4:111S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/64\">",
"      Bhattarakosol P, Yoosook C, Cross A. Intratypic variation of herpes simplex virus type 2 isolates detected by monoclonal antibodies against viral glycoproteins. Arch Virol 1990; 115:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/65\">",
"      Svennerholm B, Olofsson S, Jeansson S, et al. Herpes simplex virus type-selective enzyme-linked immunosorbent assay with Helix pomatia lectin-purified antigens. J Clin Microbiol 1984; 19:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/66\">",
"      Lee FK, Pereira L, Griffin C, et al. A novel glycoprotein for detection of herpes simplex virus type 1-specific antibodies. J Virol Methods 1986; 14:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/67\">",
"      Such&aacute;nkov&aacute; A, Hirsch I, Kr��m&aacute;r M, Vonka V. Determination of herpes simplex virus type-specific antibodies by solid-phase RIA on Helix pomatia lectin-purified antigens. J Infect Dis 1984; 149:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/68\">",
"      Slomka MJ, Ashley RL, Cowan FM, et al. Monoclonal antibody blocking tests for the detection of HSV-1- and HSV-2-specific humoral responses: comparison with western blot assay. J Virol Methods 1995; 55:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/69\">",
"      Gargiulo F, De Francesco MA, Nascimbeni G, et al. Polymerase chain reaction as a rapid diagnostic tool for therapy of acute retinal necrosis syndrome. J Med Virol 2003; 69:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/20/40265/abstract/70\">",
"      Asano S, Yoshikawa T, Kimura H, et al. Monitoring herpesvirus DNA in three cases of acute retinal necrosis by real-time PCR. J Clin Virol 2004; 29:206.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8334 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40265=[""].join("\n");
var outline_f39_20_40265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2029158\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRIMARY INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RECURRENT INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Burns and other skin disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ORAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER CUTANEOUS MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13886328\">",
"      Herpetic whitlow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13886336\">",
"      Herpes gladiatorum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13886374\">",
"      Erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31627071\">",
"      Eczema herpeticum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GENITAL HSV-1 INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OCULAR INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute retinal necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Conjunctivitis and blepharitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chorioretinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      NEUROLOGIC SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HEPATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RESPIRATORY TRACT INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      HSV ESOPHAGITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Viral culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Immunofluorescence staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Tzanck smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2029158\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8334\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8334|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/30/9696\" title=\"picture 1\">",
"      Herpetic whitlow finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/18/15650\" title=\"picture 2\">",
"      Erythema multiforme palm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/57/23443\" title=\"picture 3\">",
"      Eczema herpeticum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/6/8289\" title=\"picture 4\">",
"      Herpes simplex keratitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/3/15417?source=related_link\">",
"      Aseptic meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36216?source=related_link\">",
"      Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5738?source=related_link\">",
"      Evaluation of acute pharyngitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33992?source=related_link\">",
"      Herpes simplex keratitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6647?source=related_link\">",
"      Herpes simplex virus infection of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25786?source=related_link\">",
"      Oral lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34789?source=related_link\">",
"      PCR testing for the diagnosis of herpes simplex virus in patients with encephalitis or meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/24/4482?source=related_link\">",
"      Patient information: Cold sores (oral herpes) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/3/36916?source=related_link\">",
"      Patient information: Genital herpes (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_20_40266="Subungual onychomycosis";
var content_f39_20_40266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85579%7EDERM%2F72013%7EDERM%2F81063%7EDERM%2F74473%7EDERM%2F61687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85579%7EDERM%2F72013%7EDERM%2F81063%7EDERM%2F74473%7EDERM%2F61687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Distal subungual onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Distal subungual onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nail discoloration and subungual hyperkeratosis are present on the nail. The area immediately adjacent to the cuticle is not yet involved.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal subungual onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Proximal, white discoloration of the nail plate is noted. The nail fold is uninvolved.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Proximal subungual onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whitish discoloration originating under the surface of the proximal nail plate is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Proximal subungual onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whitish discoloration originating under the surface of the proximal nail plate is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40266=[""].join("\n");
var outline_f39_20_40266=null;
var title_f39_20_40267="Mast cell mediators in SM";
var content_f39_20_40267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effects of mast cell mediators in mastocytosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Histamine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pruritus, urticaria, gastric hypersecretion, bronchoconstriction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased vasopermeability and systemic hypotension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Heparin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Local anticoagulation, osteopenia, and osteoporosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Proteases (Tryptases, Chymase)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fibrinogen degradation, stimulation of fibroblast proliferation, activation of procollagenase and tissue remodeling (degrade fibronectin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Cysteinyl leukotrienes (LTD4, LTC4, LTE4)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased vasopermeability, vasodilation, bronchoconstriction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Prostaglandins (PGD2)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vasodilation, bronchoconstriction, flushing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Platelet activating factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased vasopermeability, vasodilation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Cytokines (TNFalpha, TGFbeta, Nerve Growth Factor)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Activation of vascular endothelial cells, cachexia fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Growth factors (IL-3, IL-5, IL-6)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mast cell and eosinophil proliferation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B cell proliferation with polyclonal increase in immunoglobulins and paraproteins",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40267=[""].join("\n");
var outline_f39_20_40267=null;
var title_f39_20_40268="Survival decompensated HBV";
var content_f39_20_40268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival after decompensation in HBV-related cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 213px; background-image: url(data:image/gif;base64,R0lGODlhXwHVANUAAP///4CAgH9/f/8AAAAAAEBAQMDAwNDQ0BAQECAgIKCgoPDw8DAwMGBgYHBwcODg4LCwsFBQUJCQkP8vL//v7/8PD/+fn/+vr/8fH/9/f//f3z8/P/8/P/+Pj/9fX/9PT//PzwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABfAdUAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en2QLBg9DDxIBEEMLCgEKC6CwsWkGEQQBQg8ICAwEDkK8BQQMssTFYATItwAOBBIACAQLEAQRALWpRwYB29zd3t/g4eLj5OXm5+jp6uvs7e7v7AZyAbZCwfL39Lf6SAEbAwMECBxIsKDBgwgTKlzIsKHDhxAjSpxIsaLFhxuUweEH4F5HAtrqcTQSQABAYyj/CND4huM1ALwOSOi1rFk/kwNS6tyzMo6B/wYEGshTQG1aAgAPCCQwkIAAqSMlT+6caqcnHGRYhTiAxuCAEAVNEyhIEjUn1bNyrC4qiWGABbRw3ahVVNLCAAxx86qZm6gkAKl6A5Phi8gvYMGIvxA+5Lft28SQuSw25NcuBgqRM2OZXMgvgAkDJmDWTFoKZ0KeKYCeULr1k9ODPAOgcNi17SOwBcn+a/a27yK5A+2u/dt3cEC7Kwy4ULz58T+7PQzw0Lz4cz+7LwyoMLq67et9dn8O3d17afB8xKsObd41+j3iZxNvD/m9nvi86Z9n2VfAkfn6CWZfHvgBGKBeA+JRYG8HJpbgHQs2GNmDTUggTxQHGOAVLqMwEf+hhA7y90UwCUjw1BIHNEVAAUIAhUwDS3wIooAienGAAypGgA0SC+giDykHCAMTARve9B+DM+ZFYROrQINMNUgQVUAEBcjDz0hQ+WeEgUlOteQSzLyoQAMs9rMiMwgscGU9ZGlZBJdd6vSlEgUw4EoT/OQjEptGbolknGfNmUSHABxwIhJBFrBAUw8EOUxMSsgIKFqCIlGAMgGUqYSLBIwFAKcwRuomEXBOWkylRRxQAAIJFLCqpko8QCiHh/b55p+mylnjFgZghQwCO4Ihaa47oWqEA56WMSyxKRnrxrLMGuOsECAFgxWsX0AbLTHTdnSjq676IsaCAJVrbrnbetL/7Rrknutuup10C06ywo76RKnwQtKtr9eOgR8T+ObrSLcGFGywhv7a60TAAjNC8AIZGlxkvVMw3LAi+xpgLTLYevHvEhZfjIi8D7DCDb3ZKtxEyCIbsq4QokwcxsdKsNwyIS8ThQwDr4yrMsC43jzwrlywGgAzoc78M8hBC+0w0VsgcKEDHXdBcxI2Ow0IwT85UHADUCpdcdNaJ7IvvysmPHbZkcj7DcoeL10z2Wy7DHVscmNNd904352FAk6m7fPafDfycgJNrZo0xVJkXXgeLxMwzTKL89gANGWCpRTcRVyNhOOP3xG5AQwEQCUTvARgQCpJLcWoqISHbrbfWDDQ/wA9NCkxTQSnvDKTL8w402bssh/y8hASCB+pUrwctSbUnh/p7rvF83E8BAGY6GE9vIS0D59Zjj39udVbT/sVYRKAgMxGTANjTLtbIznsXoBefhmRR7A6AmEnwQsvoQKGkOjXBfvdbwyHu1CmmLCKVqiCFXciIBcMeMAwuI1K25iS2uq3twqy4Wz8qhoXote4DnpwL+ejwsEktsECmvCEaDgeABBGBhJGgYIwlEwKq3AAJ/GshRN8YQ7xt0MqIO5oCKhc3L6AwyFmYXRCWODgOOjEtBRxCgnQHwRsB8QtNLGKVsgZVtbXRS2Mb3xgFMPxDpC9WqWMiWekXhoVc0UpuP/qDDak4hzpWEMRvpENX9zjEF7GDHCJS2yAFKIgnfCyjQkOkWsI5CJliMe8iSGO5lpkFF62AKrpqIaWDAMm0aXJ19QxCo4M1h/vIMkKRu4WC2CAH7WQxzS08oAv+yQATFfGOdzyfi9rQKsKgLgCHHKJePhl+RqJtlleoZZoGGUmS0lJM0DzDNIkpSar+YQFuGpDmhNLjEKpB2W2jJtOsNaPlMIUp0hwEOYUGTqZIAFWgQQAv6uJ8sJniHhebJ6xQoAEPPK8dwrCnw3rFrgWeswjRAABAWhKAx5Q0OH1U5G4PKUT0PZIJFBtVcI4QPxeYtFC4EsDF8gABypQgQ90AAT/sgMoEzwypGAMw6CBAAxKVaqcbAIEA48p28sOQKVwOYEVT2lgBEtKCJ9WgAMZuIAGQNCBD/TUp1iVpnE0+gRe9GuKJjXXU6OqgShYoC1ZTSv5bhM5onyKq3giZ2sQuonRLYVqvWwOXTVxuAC4qH+rbM9eMzHUAywgAhHoGSQFi1G4vMwAigVlgNQ6Sm7BtQnBaIAqGUcfymLSsmRQgFdLlNeGDZYnl3WCqjoa2JudVg8586pASyuw10IutUvI7GZb2zLb4uGxkaVtvnwrOtwiAbIRKxj7rCZXZhG3KsY9QrV85UwsXHNSz60DyUy2Dc6NsLnE8qx4x0teOQ4yuscN/y5YhVbe9ro3rUZgpmaVBd5S3ja0o90nb+07CBmutrrPrC9/oYvfX+kXmQMuhHx3i+AE9xe92VDvYh0ciEYCmAgDLUADenYAMjVguUO4LoXh8DIpPmFFiQNAjyCqCwlHUcAjJjGEj7UiozKBFAtABgCIAiOgeHeXMI6xXGZcBEdeeIZpqyg/hawSImMhlmRUMkmCzOQ1EJKhTeghGXcclE91iqlVRi0ZjMyEHgrjmysOQIvBHOb7niEBDCaCqhbqlQ5rGMQvbnMfqilL4eo5DleuEzX8/Oc3MBMZCcAzLalc6ME4mQ0ibrSjxcBGr1AtzluItKTV+GgcLWAmyLjQhP83bUUxGPMjolUic0lN4DBcCgDq2+WRqaBpVnuhW1sBSjXIRGhbn6FbuQh1jx4NZF/PYV1slAcb3bhqYwOa2GqotbOfCO00SHvaV5ApZ7H9wWqj4drcpoK29xtuM4y7weWOobcrmW4rr9uajG73FM7dbHn/+t30tbe6GwFufTOB3ktQqouJ0G9/KwHgShDgTXFq8FvjWwojnR/DG65D+OzpbgWneHwfHgUpL1njfNRDPoMXow1c5OQoT7nKV87ylrtc5RnZQ+vayWwiaAMeOM+5znfO8577/Oc8F3UewvljkBv96EhPutKXzvSmO/3ppmJjABRdhgYGoOZpyBDWz2D/Cge6oetFJwMNVQzBgSvCKE3BdA3HuPUymJnjRCAKAjTYBi0DYw1sfKTCJxETR7mhQ7WA+xC8KnikKMXs1qSJjtVgrTJFXO2HWPzi3+DjZyGAGYWfCQOgcWA0mLkWYQ9Dr8rk8UZIngBw8HvdJYelaAcFAtBouxgewIAEQEPVZRh9FC8uCWgsIMcIeAPgftgG3GFF8DO5BU3XUAvINkXoZ9A9PmlC8kgAZRtdbsNMLu/1NcjqJ0GRfRhaB/s0tQEomo29GmQiDMjO/HWROOyTED8GMrcEfGsIJ9XHIH9hQH5EvjIUYRF6UFeABniACJiACnhCBfMUWreAmEAPLLJipfQHgYuwKKxnE2oyJdjwUR82Q1OnAPKQYQ4gfhYoB0YxQJsXAJCSAEjkPOpjC0DhACwIfSeoB9ZSZyviV/VgAFQDDbskcbUQAapzg38gfaPHDatTFLwQhBeyAA3gVf9nhHAgfc+AACIoAaxgCxDQFE7YIhZSfVSoB1ZIVIgGAbGkFF5IDwoEDZc3hnAYh3I4h3RYh3Z4h3iYh3q4h3zYh374h5ARBAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative probability of survival in patients with cirrhosis related to hepatitis B virus (HBV) infection after the first major complication.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fattovich G, Giustina G, Schalm SW, et al. Hepatology 1995; 21:77.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40268=[""].join("\n");
var outline_f39_20_40268=null;
var title_f39_20_40269="Low-efficiency acute renal replacement therapies";
var content_f39_20_40269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Figure showing different types of low efficiency acute renal replacement therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 326px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Marshall MR, Golper TA. Low-efficiency acute renal replacement therapy: role in acute kidney injury. Semin Dial 2011; 24:142. Copyright &copy; 2011. Reproduced with permission of John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40269=[""].join("\n");
var outline_f39_20_40269=null;
var title_f39_20_40270="RMSF rash";
var content_f39_20_40270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rocky mountain spotted fever rash",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 178px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Child with Rocky Mountain spotted fever has the rash that is characteristic but typically does not appear until several days after fever onset.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Fatal Cases of Rocky Mountain Spotted Fever in Family Clusters --- Three States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53(19):407.&nbsp;",
"     <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5319a1.htm\" target=\"_blank\">",
"      file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5319a1.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40270=[""].join("\n");
var outline_f39_20_40270=null;
var title_f39_20_40271="Testost formation metabolism";
var content_f39_20_40271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Testosterone formation and metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 457px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_20_40271=[""].join("\n");
var outline_f39_20_40271=null;
